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Abstract
Background: In the last decade, several new antihyperglycemic medications have been
approved to treat people with diabetes. However, the hypoglycemia risk of these medications
in older adults in routine clinical practice remains unclear. Further, there is limited
understanding as to how these medications are being prescribed to older adults in our region.
Methods: We carried out retrospective, population-based studies of adults age 66 and older
in Ontario, Canada using linked healthcare databases. We first investigated the real-world
hypoglycemia risk of 2 antihyperglycemic medications – glyburide and modified-release
gliclazide. In an ecological study, we then examined trends in antihyperglycemic medication
prescriptions, and in this setting, investigated hospital encounters for hypoglycemia.
Results: Initiating glyburide vs gliclazide as monotherapy or in the presence of metformin
was associated with a significantly higher risk of a hospital encounter with hypoglycemia.
Over the last decade, newer and safer antihyperglycemic medications have been prescribed to
older adults in our region. In this setting, the overall percentage of patients with a hospital
encounter with hypoglycemia has declined.
Conclusions: Antihyperglycemic medications differ in their real-world hypoglycemia risk in
older patients. In the setting of newer and safer antihyperglycemic medications, encounters
for hypoglycemia have declined.
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Chapter 1

1

Introduction

1.1 What is diabetes?
Diabetes is a chronic metabolic condition characterized by insulin deficiency, impaired
secretion and/or insulin resistance (ie poor utilization). As insulin aids in the storage and
utilization of glucose,1,2 patients with diabetes have elevated blood sugar or
hyperglycemia. The Canadian Diabetes Association currently recommends that a
diagnosis of diabetes be made in an individual with: 1) a fasting blood glucose ≥7
mmol/L, or 2) a 2 hour blood glucose ≥11.1 mmol/L following a 75 gram oral glucose
tolerance test, or 3) a random blood glucose ≥11.1 mmol/L or 4) a glycosylated
hemoglobin (HbA1c) greater than 6.5% (a test that reflects glycemic control over the
previous 8-12 weeks).3
There are two main types of diabetes - type 1 diabetes and type 2 diabetes. Type 1
diabetes is the result of pancreatic beta-cell destruction, most commonly from an
autoimmune process.4 This leads to insulin deficiency and these patients require insulin
replacement therapy.1 Type 1 diabetes can occur at any age but is more common in
childhood and adolescence. It accounts for approximately 5% of all patients with
diabetes.2
Type 2 diabetes is characterized by insulin resistance and impaired insulin secretion.2
Although genetic factors play a role in its development, it is closely related to obesity and
decreased physical activity.5 As such, these patients often have concomitant medical
conditions including lipid disorders and high blood pressure (the “metabolic
syndrome”).1 Most people with type 2 diabetes do not need insulin initially, but with
time, often require it to maintain adequate glycemic control.1 Type 2 diabetes typically
arises in adulthood, though it is increasing in onset in younger individuals. It accounts for
about 95% of patients with diabetes.2
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1.2

What is the burden of diabetes?

The number of people with type 1 and type 2 diabetes is increasing in North America and
worldwide.4,6 In 2013 there were almost 2 million people over the age of 12 with the
condition in Canada, and almost 900,000 were age 65 and older.7 Where sedentary habits
and obesity are epidemic, this trend is expected to continue, especially in type 2
diabetes.6
Diabetes can lead to significant consequences for patients including structural
complications, treatment related side effects, impaired quality of life, and premature
death (detailed below). The disease is also associated with major economic burden, and
has consumed an increasing proportion of provincial health care expenditures.8 From
2000 until 2010, the economic burden of diabetes (direct and indirect costs) was
estimated to double ($6.3 billion in 2000, $12.2 billion in 2010). By 2020, it has been
projected that its associated costs will increase by another $4.7 billion.8

1.3

What are the consequences of diabetes?

Diabetes can have several significant consequences for patients. Acutely, hyperglycemia
can lead to symptoms including frequent urination and blurred vision.1 Weight loss may
occur through the depletion of water and nutrient stores, and dizziness and weakness can
result from lowered plasma volume.1 In severe instances, diabetic ketoacidosis or
hyperglycemic hyperosmolar state (ie. hyperglycemic emergencies) can arise which may
lead to hospital presentation, morbidity and mortality.9
Over the longer term, hyperglycemia can also result in small and large blood vessel
damage. Small vessel damage, termed microvascular disease, typically impacts the
kidney (nephropathy), nerves (neuropathy), and eyes (retinopathy). Diabetic nephropathy
initially manifests as protein loss in the urine (proteinuria) and eventually can lead to
chronic kidney disease.1 Neuropathy can involve the sensory, motor and autonomic
nerves and can result in loss of vibration sense and temperature along with pain, impaired
reflexes, joint and connective tissue changes, low blood pressure, impaired gastrointestinal activity (ie. gastroparesis), and bladder and erectile dysfunction.1 Diabetic

3

retinopathy can lead to vision loss as a result of hemorrhage, microaneurysms, exudates,
retinal detachment and macular edema.1
Chronic hyperglycemia can also lead to large vessel or macrovascular disease which
impacts the vessels of the heart (cardiovascular), brain (cerebrovascular) and periphery
(peripheral vascular). Cardiovascular disease may lead to heart attack and heart failure.
Peripheral vascular disease may cause ischemia of the lower extremities, erectile
dysfunction, intestinal angina and gangrene.1 Cerebrovascular disease may result in
stroke or transient ischemic attack.
Other recognized complications of diabetes include bony fractures,10 skin changes, and
chronic infections.1 In the elderly, depression, impaired cognition, urinary incontinence
and chronic pain have also been identified.11 Life expectancy is 3 to 6 years shorter in
patients over the age of 65 with diabetes compared to those without the condition.11

1.4

How is diabetes managed?

The management of diabetes involves treating hyperglycemia and managing its related
complications.12

1.4.1

Hyperglycemia

Central to the management of diabetes is controlling hyperglycemia. The target for
glycemic control for most patients with diabetes is an HbA1c less than 7%. This is based
upon studies which have indicated that an HbA1c less than 7% reduces the risk of
microvascular complications, and in younger patients with a recent diagnosis of the
disease, macrovascular complications.13–17
Glycemic control can be accomplished through lifestyle modification and/or the initiation
of antihyperglycemic medications. Lifestyle modification (including exercise, healthy
diet, and weight control), can have a significant impact on blood sugars. In fact, for type
2 diabetes, lifestyle changes are considered first line therapy. In a meta-analysis of the
effects of exercise on glycemic control, it was found that aerobic, resistance and
combination exercise programs improved glycemia.18 Likewise, nutritional therapy with
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a registered dietitian can lower HbA1c by 1 to 2%.19 The impact of weight loss on
glycemic control is supported by recent studies on the benefits of bariatric surgery in type
2 diabetes .20 Physicians who treat diabetes usually aim for multi-factorial lifestyle
intervention based upon the benefits reported by the Diabetes Prevention Program (DPP)
Trial,21 and the LOOKAHEAD trial which indicated that patients randomized to an
intensive lifestyle (healthy diet and 175 minutes of physical activity per week to induce at
least 7% weight loss) had a lower HbA1c after 4 years compared to those randomized to
diabetes support and education alone (HbA1c -0.36% vs -0.09%, p<0.001).22
Beyond lifestyle modification, antihyperglycemic medications can help to improve
glycemic control. These medications can include insulin (for both type 1 and 2 patients)
or other oral/subcutaneous antihyperglycemic medications (for patients with type 2
diabetes). Where only sulphonylureas (eg. glyburide), biguanides (eg. metformin),
insulin, and alpha glucosidase inhibitors (eg. acarbose) were available for the treatment of
type 2 diabetes in Canada in the 1990’s, there are now 20 different antihyperglycemic
medications approved for use in our country, each with different benefits and side effect
profiles (list of available drugs, potency, side effects presented in Table 1).
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Table 1. Antihyperglycemic medications currently available in Canada
Class

Drug Names

Mechanism of

Glucose

Weight

Hypoglycemic

Available

Action

Lowering

Effect

Risk

Side Effects

Notes

Effect

Biguanides

Metformin

Decreases hepatic

Reduces

Weight

Negligible risk

Gastrointestinal

Considered first

glucose output;

HbA1c by

loss

as monotherapy 6

upset, lactic

line therapy for

acidosis (esp in

type 2 diabetes by

those with renal,

most clinical

liver, heart failure)

practice guidelines

enhances insulin

1.5%

24

reported

25

effect at peripheral
receptors

23

6

Alpha glucosidase

Acarbose

inhibitors

Inhibits the intestinal

Reduces

enzyme that breaks

Neutral

Negligible risk

Gastrointestinal

HbA1c by

as monotherapy

upset

down polysaccharides

0.5-0.8%

23

and reduces

24

carbohydrate reabsorption1
Insulin

Bolus: Aspart,

Binds to receptor on

Reduces

Associated

Very high risk of

For treatment of

Glulisine, Lispro,

surface of target cell

HbA1c by

with

hypoglycemia

type 1 and type 2

Regular

membrane leading to

1.5-2.5%

weight

increased glycogen,

24

Basal: NPH,

lipid and protein

gain

24

diabetes. Need
consideration of
patient function,

6

Detemir, Glargine
Pre-mixed:
Regular/NPH
(30/70, 40/60,
50/50), Biphasic

synthesis; triggers

autonomy,

genes involved in

cognition, vision,

growth and

self-management

metabolism; promotes

ability. No dose

the storage of

ceiling and flexible
1

regimens27

ingested nutrients

aspart (novomix 30),
Lispro/protamine
(Humalog mix 25,
50)26
Sulphonylureas

Glyburide,

Bind to sulphonylurea

Reduces

Associated

High risk of

Often considered

Gliclazide,

receptor on the beta

HbA1c by

with

hypoglycemia

second line agent

Glimepiride,

cell of the pancreas to

Acetohexamide,

inhibit potassium

Chlorpropamide,

efflux; leads to

Tolbutamide

depolarization of beta

24

1.5%

weight

to metformin in

gain 25

type 2 diabetes

cell and insulin
release 25
Thiazolidinediones

Pioglitazone,

Bind to perioxisome

Reduce

Weight

Negligible risk

Edema, heart

Rosiglitazone

proliferator activated

HbA1c by

neutral

of hypoglycemia

failure, fracture,

receptors; increase

0.5 to

as monotherapy

hepatotoxicity.

sensitivity of muscle
fat, and liver to

24

1.4%

Rosiglitazone
potentially linked

7

insulin1

to adverse
cardiovascular
events6,25

Meglitinides

Repaglinide,

Bind to sulphonylurea

Reduce

Associated

Risk of

Rapid onset of

Nateglinide

receptor and induce

HbA1c by

with

hypoglycemia

action so can be

weight

(though less than

dosed prior to

with

meals

the depolarization of

24

1-1.5%

pancreatic beta cells

gain

6

23

to secrete insulin

sulphonylureas)

Dipeptidyl

Sitagliptin,

Inhibit the enzyme

Reduce

Weight

Negligible risk

Gastrointestinal

peptidase-4

Saxagliptin,

degradation of

HbA1c by

neutral

of hypoglycemia

upset,

as monotherapy

nasopharyngitis,

inhibitors

Linagliptin

glucagon like peptide-

24

0.5-1%

1; suppress glucose

headache

release, delays gastric
emptying and
stimulates insulin
release from the
pancreas in a glucose
dependent fashion 25
Glucagon like

Exenatide,

Glucagon like

Reduce

Associated

Negligible risk

Gastrointestinal

Subcutaneous

peptide-1 agonists

Liraglutide

peptide-1 stimulates

HbA1c by

with

as monotherapy

discomfort

injection

insulin release from

0.5 to

weight loss

the pancreas in a

1%24

24

8

glucose dependent
fashion23
Sodium glucose co-

Canagliflozin,

Inhibit renal

Reduce

Associated

Negligible risk

Genital mycotic

transporter 2

Dapagliflozin

reabsorption of

HbA1c by

with

as monotherapy

infections, osmotic

about

weight loss

inhibitors

glucose

28

0.7%

diuresis and
volume depletion
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1.4.2

Diabetes-related complications

In addition to managing hyperglycemia, physicians who treat diabetes must also address
its related complications.
Alongside tight glycemic control, kidney health can be optimized through control of
blood pressure and the use of angiotensin converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARB’ s).29–32 Eye health can be promoted through blood
pressure control and smoking cessation.1 In those with advanced retinopathy,
photocoagulation can reduce severe visual loss.1,33 Neuropathy-associated conditions
including gastroparesis can be managed with medications including dopamine
antagonists (eg. metoclopramide, domperidone) and erythromycin. Erectile dysfunction
can be treated with cyclic guanosine monophosphate-specific phosphodiesterase type 5
inhibitors.1,34 Painful diabetic neuropathy can be treated with anticonvulsants,
antidepressants, opioids, topical nitrates, and capsaicin.34
In addition to lifestyle modification, the cardiovascular health of patients can be
optimized with smoking cessation,35 the use of lipid-lowering medications,36,37 the control
of blood pressure,38 antiplatelet therapy (in those with a previous cardiovascular event or
at high risk of an event),39 and ACE inhibitors or ARB’s.32,40,41 A multifactorial strategy
to improve cardiovascular health is especially beneficial as illustrated by the STENO 2
trial. In this trial, patients randomized to intensive therapy (ie. tight glucose control, ACE
inhibitors or ARB’s, aspirin and lipid lowering therapy) had both a lower risk of death
from cardiovascular causes (hazard ratio (HR) 0.43 [95% confidence interval (CI) 0.19 to
0.95], p=0.04] and a lower risk of cardiovascular events (HR 0.41 [95% CI 0.25 to 0.67],
p<0.001) compared with those randomized to standard care.42
Finally foot health can be maintained through regular physical examination, education,
the optimization of vascular health, the use of proper footwear, and early referral should
foot complications occur.43 For those with evidence of skin ulcers, local wound care,
debridement and mechanical unloading are important interventions.1,43
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1.5
What are the complications of diabetes
management?
1.5.1

Hypoglycemia

Because antihyperglycemic medications by design lower blood glucose levels, a
significant complication of diabetes management is hypoglycemia. Though definitions
vary, the Canadian Diabetes Association defines hypoglycemia by 1) the development of
symptoms (eg. shaking, tremor); 2) a low plasma glucose level (<4.0 mmol/L); and 3) the
relief of symptoms with carbohydrate administration.44 The severity of hypoglycemia is
best defined by whether a patient can self-treat their episode with the ingestion of
carbohydrate (mild) or if they need assistance for treatment from another person
(severe).45
In addition to producing uncomfortable symptoms including tremor, lightheadedness,
palpitations, sweating, anxiety, hunger, nausea, tingling, vision changes, and headaches,
44

hypoglycemia can have other significant consequences for patients.

Motor activities and coordination can be impacted leading to falls, injury and fracture.45
Reaction times can also be prolonged and often do not return to baseline until 20-30
minutes after normal blood glucose levels are restored.46 As a result, activities including
driving performance can deteriorate.
Hypoglycemia can also lead to neurological dysfunction including decreased level of
consciousness, coma, stroke, transient ischemic attack and seizures.45 In the elderly there
is additionally increasing evidence that recurrent exposure to severe episodes of
hypoglycemia can have detrimental effects on cognitive function and may promote the
development of dementia.45 In a study of 16,667 older patients with type 2 diabetes, the
age-adjusted incidence rates of dementia were elevated for those with at least 1 severe
hypoglycemic episode compared with those with no episodes (567 cases per 10,000
person years [95% CI 497 to 637 per 10,000 person-years] vs 328 cases per 10,000
person years [95% CI 311 to 343 per 10,000 person years], adjusted HR 1.68 [95% CI
1.47 to 1.93]). In this study, the risk of dementia also increased with a greater number of
hypoglycemic events.47
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Additionally, the release of stress hormones in the setting of hypoglycemia can impact
the cardiovascular system. In those with heart disease, hypoglycemia has been linked
with heart attack, heart failure, and irregular heart rhythms.45
Further, it has been recognized that hypoglycemia has a significant impact on quality of
life. Barnett et al found that hypoglycemia was independently associated with reduced
quality of life and additionally noted that the magnitude of the quality of life reduction
increased with the severity and frequency of hypoglycemia symptoms.46 Events can also
lead to adverse consequences in the work place, in social relationships and in the
educational environment.45
Hypoglycemia has also been associated with death. “Dead in bed syndrome” has been
described in case reports of patients with type 1 diabetes with documented nocturnal
hypoglycemia (by real-time glucose monitoring) who died in their sleep.46 In a casecontrol study of hospitalized patients, it has also been found that insulin-associated and
spontaneous hypoglycemia was associated with increased mortality.48
Additional consequences of hypoglycemia include a fear of ongoing events which may
prompt avoiding behaviour and poor adherence to diabetes treatment.45,46 Chronic
hypoglycemia can also impair defenses against subsequent falling plasma glucose
concentrations and may lead to a cycle of recurrent hypoglycemia.46

1.5.2

Additional risk factors for hypoglycemia

Beyond the use of antihyperglycemic medications, several risk factors have been
established for hypoglycemia. Those with type 1 diabetes 45 and advanced type 2 diabetes
46

are at increased risk along with those with either tightly controlled or poorly controlled

blood sugar.49,50 Compared with patients using thiazolidinediones, metformin, dipeptidyl
peptidase-4 inhibitors (DPP-4), glucagon like peptide-1 agonists (GLP-1), and sodium
glucose co-transporter 2 inhibitors (SGLT2), those using insulin, sulphonylureas and
meglitinides are also at higher risk of hypoglycemia (Table 1).45
Several comorbidities also place patients at increased risk of hypoglycemia. These
include nephropathy, cognitive dysfunction, alcohol use, neuropathy and hypoglycemia
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unawareness (impaired awareness of hypoglycemia symptoms).45 The elderly are at
particular risk of hypoglycemia as they have impaired counter-regulatory responses,51
tend to have few warning symptoms,51,52 and recover more slowly from events.45

1.6
Special issues in older adults and the need for
research
Glycemic control is a central issue in the management of patients with diabetes.
However a significant practical problem for clinicians is finding a balance between
control that is adequate to prevent symptoms and reduce the risk for structural
complications, and the cost of unacceptable side effects including hypoglycemia. This
risk to benefit ratio is particularly poorly understood in older patients - a heterogeneous
population with different life expectancies, functionalities, comorbidities, levels of frailty
(marker of vulnerability which identifies patients with a diminished capacity to
compensate effectively for external stresses and disability)53 and durations of disease. 6
Further adding to their treatment complexity is the recent proliferation of
antihyperglycemic medications that have become available to treat people with diabetes
in the last decade. In the older adult population, there has been limited study into the
efficacy of these medications,10,54 their hypoglycemia risk (Table 2), and their use in this
vulnerable population.

1.7

Research aims

In the current work we aimed to expand our knowledge of antihyperglycemic medication
prescribing and safety in older adults with diabetes. Our specific aims were to:
1) Investigate the real-world risk of hypoglycemia for new users of glyburide vs
modified-release gliclazide (2 sulphonylurea medications).
2) Investigate patterns in antihyperglycemic medication prescriptions in older adults from
2002 until 2013, and over the period of study, investigate hospital encounters for
hypoglycemia.
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Table 2. Real-world studies on the efficacy and safety of antihyperglycemic
medications
Authors

Study Design

Results

Conclusions

Mathieu C

Multicentre prospective

Mean age 57.8± 11.8, 12, 917

Compared with other

observational cohort study

(29.5%) over the age of 65.

medications,

et al

55

of 45,868 adults with type
2 diabetes inadequately
controlled on 1
antihyperglycemic
medication.

vildagliptin can lower
Noted better treatment response and
tolerability with vildagliptin

HbA1c to target
without side effects.

compared with other
antihyperglycemic medications
(adjusted odds ratio 1.49 [CI 1.42-

Examined treatment

1.55], p<0.001).

response and tolerability to
vildagliptin vs. other oral
agents (including risk of
hypoglycemia).

Al-Arouj
56

M et al

Multicentre prospective

Mean age 49.6 with 10% over the age

Vildagliptin was

study from the Middle

of 65.

associated with

East and Asia of type 2
patients over the age of 18
treated with vildagliptin
(n=684) or sulphonylurea
(n=631) as add on to
metformin.

significantly fewer
Significantly fewer patients in the
vildagliptin group experienced a
hypoglycemia event compared with
those receiving sulphonylureas (5.4%
vs 19.8%, p<0.001).

hypoglycemia
episodes compared
with sulphonylureas
and was welltolerated in this
population.

Primary outcome was the
proportion with at least 1
hypoglycemia event
during the fasting period in
Ramadan.
Freemantle
N et al

57

Multicentre, prospective

Propensity score matches achieved for

Less nocturnal

cohort study of type 2

686 starting premix vs basal insulin,

hypoglycemia with

14

patients over the age of 40

542 starting basal and mealtime vs

basal insulin than

who started insulin within

premix, 400 starting basal and

premix.

12 months prior to study

mealtime (ie bolus).

entry (n= 2374).
Mean age was approximately 60
Aimed to examine the

across groups. HbA1c reduction did

performance of different

not differ between the 3 insulin

insulin regimens on

regimens. Relative risk of overall and

HbA1c reduction and

nocturnal hypoglycemia lower

hypoglycemia along with

(p=0.010 to p<0.001) with basal or

body weight change.

basal plus mealtime compared with
premix. Similar finding for nocturnal
(p=0.021) hypoglycemia but not for
overall hypoglycemia for basal
compared with basal and mealtime
regimens.

Gitt AK et
58

al

German prospective cohort

884 received dual therapy with DPP-4

DPP-4 on top of

study of 3810 patients with

or sulphonylurea in setting of

metformin resulted in

type 2 diabetes over the

metformin (n=628 and n=256

similar HbA1c

age of 40 on mono or dual

respectively). Mean age 64.1 in DPP-

reductions within 12

combination therapy prior

4 group and 67.9 in SU group.

months with a

to study.

significant reduction
No significant difference in change in

Aimed to examine if DPP-

HbA1c over the 12 months of

4 inhibitor compared to

treatment but hypoglycemia

sulphonylurea provided

significantly less frequent in those

non-inferior glycemic

receiving DPP-4 inhibitors (odds ratio

control with reductions in

0.32 [95% CI 0.19 to 0.54]).

in hypoglycemia.

body weight and lower
risk of hypoglycemia.

Holstein et
59

al

Prospective cohort study

Glimepiride produced fewer episodes

In people with type 2

of 30,768 patients who

of hypoglycemia than glyburide

diabetes, glimepiride

attended the emergency

(0.86/1000 person-years vs. 5.6/1000

associated with fewer

room over a 4 year period.

person years respectively).

episodes of severe

15

hypoglycemia than
Aimed to evaluate the
incidence of severe

glyburide in routine
care.

hypoglycemia associated
with glimepiride and
glyburide.
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2.1 Introduction
Sulphonylureas are easy to administer, low in cost, and through their insulin secreting
mechanism, are amongst the most potent of all oral hypoglycemic agents.1,2 These drugs
however, must be used very carefully in older adults to avoid hypoglycemia, given that
this population frequently has medical comorbidities, takes multiple medications, and has
altered drug metabolism.
In Canada, glyburide (glibenclamide) and gliclazide are 2 commonly prescribed
sulphonylureas. Because of glyburide’s high affinity for the sulphonylurea receptor,3 its
long duration of action, and its glucose lowering metabolites,4 the hypoglycemia risk of
glyburide is anticipated to be higher than other sulphonylureas.5-7 Accordingly, diabetes
guidelines have cautioned against the use of glyburide in the elderly in favor of other oral
hypoglycemic agents.8 However, to our knowledge, the risk of hypoglycemia with
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glyburide compared with a long-acting alternative, modified-release gliclazide,9 has not
been examined in a large representative population of older adults in routine practice.
For this reason we conducted 2 population-based cohort studies to examine the risk of
hospital encounters with hypoglycemia after the initiation of glyburide vs once-daily
modified-release gliclazide in the outpatient setting.

2.2
2.2.1

Methods
Study design and setting

We conducted 2 population-based matched retrospective cohort studies of older adults
using linked health care databases in Ontario, Canada. Ontario has approximately 1.8
million adults aged 65 years or older who have comprehensive universal healthcare
including coverage for outpatient prescription medications, physician services,
hospitalizations and diagnostic testing.10 The reporting of these studies follows guidelines
for observational studies (Appendix B Table 1).11
The studies were conducted at the Institute for Clinical Evaluative Sciences (ICES)
according to a pre-specified protocol which was approved by the research ethics board at
Sunnybrook Health Sciences Centre (Toronto, Canada). Participant informed consent was
not required.

2.2.2

Data sources

We obtained patient characteristics, drug use, covariate information, and outcome data
using records from several databases. We ascertained vital statistics from the Registered
Persons Database of Ontario, which contains demographic information on all Ontario
residents who have been issued a health card. The Ontario Drug Benefit Program
database was used to identify prescription drug use and contains accurate records of all
formulary prescriptions dispensed to those aged 65 years or older, with an error rate of
less than 1%.12 Diagnostic and procedural information on hospital admissions and
emergency room visits was abstracted from the Canadian Institute for Health
Information’s Discharge Abstract Database and the National Ambulatory Care Reporting
System database, respectively. Covariate information was also derived from the Ontario
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Health Insurance Plan database, which includes health claims for inpatient and outpatient
physician services. We used the ICES Physician Database to abstract sulfonylurea
prescriber information. In previous studies, we have used these databases to research
adverse drug events and health outcomes.13-18 A subpopulation of patients had laboratory
creatinine or HbA1c values available in the year prior to the relevant sulphonylurea
prescription.19,20
With the exception of sulfonylurea prescriber information (missing in approximately 13%
of both studies), and income quintile (missing in approximately 0.5% of both studies) the
databases were complete for all variables used. International Classification of Diseases
9th Revision (ICD-9) (pre-2002), International Classification of Diseases 10th Revision
(ICD-10) (post-2002), Canadian Classification of Diagnostic, Therapeutic and Surgical
Procedures (CCP) (pre-2002) and Canadian Classification of Health Interventions (CCI)
(post-2002) codes were utilized to assess baseline comorbidities and investigations in the
5 years prior to the relevant sulphonylurea prescription (Appendix B Table 2). Physician
visits in the year prior to the sulphonylurea prescription were assessed through provincial
fee for service codes. Codes used to assess outcomes are detailed in Appendix B Table 3,
which lists only ICD-10 codes as all events would have occurred after the
implementation of this coding system in Canada.

2.2.3

Patients

To mimic routine practice, we conducted 2 population-based studies of older adults
newly prescribed glyburide or modified-release gliclazide from April 2002 to December
2011. In the first study we examined a sulphonylurea prescribed as monotherapy and in
the second study we examined a sulphonylurea prescribed in the presence of metformin.
In both studies, the date of the sulphonylurea prescription served as the index date (cohort
entry date).
Monotherapy study
In this study, we excluded the following patients from analysis: 1) those in their first year
of eligibility for prescription drug coverage (aged 65 years) to avoid incomplete
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medication records, 2) those who had insulin or any other oral hypoglycemic agent
dispensed in the year prior to the index date to ensure new oral hypoglycemic agent use,
3) those who had other medications commonly associated with hypoglycemia (ie.
pentamidine, quinine, glucagon, indomethacin) dispensed in the year prior to the index
date,21 4) those with a history of at least one hospital encounter (emergency room or
hospitalization) with hypoglycemia in the 5 years prior to the index date as antecedent
hypoglycemia can be associated with hypoglycemic unawareness and recurrent
episodes,22 5) those with a history of end-stage renal disease in the 5 years prior to the
index date as reduced renal function may decrease the clearance of drugs and their
metabolites, 6) those who were discharged from hospital in the 2 days prior to or on the
index date to ensure these were new outpatient sulphonylurea prescriptions (because in
Ontario patients continuing a sulphonylurea initiated in hospital would have their
medication dispensed on the same day or the day after hospital discharge). A patient
could only enter the cohort once. Patient selection is presented in Figure 1 of Appendix
B.
Metformin combination study
In this study, in addition to either glyburide or modified-release gliclazide, patients were
required to have evidence of metformin therapy (dispensed on the index date or
dispensed at least once in the 180 days prior to the index date with the day supply
covering the index date). The exclusion criteria applied were as in the monotherapy
study, with the exception of excluding patients with oral hypoglycemic agents other than
metformin dispensed in the year prior to the index date (Appendix B Figure 2).
In each study, we restricted the analysis to comparable sulphonlyurea dosages - glyburide
total doses of 5, 10, 15, and 20 mg per day, and modified release gliclazide total doses of
30, 60, 90 and 120 mg per day.

2.2.4

Outcomes

In both studies, outcomes were assessed 90 days after the index date for the primary
analysis. We chose 90 days of follow-up to avoid crossover in drug therapy that could
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occur with longer periods of follow up, and because prescriptions covered by Ontario’s
drug plan are prescribed at no more than 100-day intervals.
The primary outcome was a hospital encounter (emergency room visit or hospital
admission) with hypoglycemia. The secondary outcome was all-cause mortality (any
death in or outside of hospital). The validity of the diagnostic codes used to identify these
outcomes is presented in Table 3 of Appendix B.

2.2.5

Statistical analysis

We used similar statistical methods in each of the 2 studies. Baseline characteristics were
compared between glyburide and gliclazide users using standardized differences. This
metric describes differences between group means relative to the pooled standard
deviation and is considered a meaningful difference if greater than 10%.23
A propensity score for the potential receipt of gliclazide was derived from a logistic
regression model where treatment status was regressed on a set of 19 and 21 baseline
covariates in each study respectively.24 Covariates were selected on the basis of their
potential association with oral hypoglycemic agent use or the study outcome, and
included comorbidities, medications, health care visits, investigations and laboratory
testing. We then retained each glyburide user who could be matched with a gliclazide
user (1:1 match). Groups were matched using a nearest neighbor “greedy” matching
algorithm on the basis of the logit of their propensity score (with a caliper width of ± 0.6
standard deviations),24 age (±2 years), the presence of chronic kidney disease, at least one
endocrinologist visit in the year prior, and the prescribed equivalent dose of glyburide or
gliclazide (5 mg of glyburide equivalent to 30 mg of modified release gliclazide).9,25-28
Matching on characteristics apart from the propensity score was completed in order to
ensure good balance on prognostically important characteristics,24 and to facilitate
potential subgroup analyses. We then assessed the degree of balance in measured
covariates between groups by examining post-match standardized differences which were
less than 10% for over 55 characteristics in both studies.
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The referent group consisted of older adults who were prescribed gliclazide. We
estimated absolute risk differences by directly examining the percentage of patients in
each treatment group with an encounter for hypoglycemia within 90 days. Absolute risk
was also expressed as the number needed to harm (NNH) which is the reciprocal of the
risk difference (1 / absolute risk difference). To account for matching, we used
conditional logistic regression to estimate unadjusted odds ratios (OR) and 95%
confidence intervals (CI’s). OR’s can be interpreted as relative risks (RR) (appropriate
given the incidences observed).
To assess the robustness of our primary outcome, we also carried out several additional
secondary analyses. These analyses were carried out after knowledge of our primary
results. First, we adjusted our conditional OR’s for the year of study cohort entry.
Further, we extended follow-up beyond 90 days, terminating the observation period for
reasons of death, study sulphonylurea discontinuation, receipt of a non-study
hypoglycemic agent, or the last date of available records (March 31, 2012) and used Cox
regression analyses stratified on matched sets.
Additionally, we performed other analyses to put the results into context and to guide the
types of physicians to target with educational initiatives. We examined the total 90-day
cost of all prescription drugs to the provincial health care program in glyburide vs.
gliclazide users and tested for a statistical difference between the cost distributions using
a Kruskal-Wallis test. We also examined physician characteristics associated with
glyburide (versus gliclazide) prescriptions in the last 3 years of study accrual using
conditional logistic regression [covariates included year since medical school graduation,
physician sex, and practicing in a rural setting (population less than 10,000)].
We conducted all analyses with SAS version 9.3 (SAS Institute, Cary, North Carolina).
We interpreted 2-tailed p values lower than 0.05 as statistically significant.
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2.3
2.3.1

Results
Monotherapy study baseline characteristics

We identified 18,804 patients prescribed glyburide (n = 13,550) or gliclazide (n = 5254).
Baseline characteristics of the 2 groups before and after matching are presented in Table
3, and the characteristics of patients with and without laboratory values available in the
year prior are illustrated in Appendix B Table 4. After matching, we retained 4374
patients in each group, and baseline characteristics were similar between the groups.
Over the course of the study, there were 4288 unique health care prescribers of glyburide
or gliclazide and approximately 78% of prescribers were primary care physicians.
Prescriptions were filled across 464 pharmacies. Over the years of accrual, glyburide
continued to be initiated in routine care. However, there was a trend to fewer initiations
over time with 609 prescriptions in 2002 (34 per 100,000 older adults in the general
population) and 132 prescriptions in 2011 (7 per 100,000 older adults). The initiation of
gliclazide increased from 6 in 2002 (at a time when the medication was not covered
under Ontario’s universal prescription drug plan) to 839 prescriptions in 2011 (47 per
100,000 older adults).

2.3.2

Monotherapy study outcomes

Prescribing glyburide was associated with a higher risk of a hospital encounter with
hypoglycemia compared with gliclazide (69 patients of 4374 taking glyburide [1.60%] vs
8 patients of 4374 taking gliclazide [0.18%], absolute risk increase 1.40% [95% CI
1.01% to 1.79%], OR 8.63 [95% CI 4.15 to 17.93], p < 0.0001). Prescribing glyburide
was not associated with a significantly higher risk of all-cause mortality compared with
gliclazide (100 patients of 4374 taking glyburide [2.29%] vs 84 patients of 4374 taking
gliclazide [1.92%], absolute risk increase 0.37% [95% CI -0.21% to 0.95%], OR 1.21
[95% CI 0.89 to 1.63], p=0.22) (Table 4).

2.3.3

Metformin combination study baseline characteristics

We identified 26,598 patients prescribed glyburide (n= 16,631) or gliclazide (n= 9967) in
the presence of metformin. Baseline characteristics of the 2 groups before and after
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matching are presented in Table 5, and the characteristics of those with and without
laboratory values available in the year prior are illustrated in Appendix B Table 4. After
matching, we retained 8038 patients in each group, and baseline characteristics were
similar between groups. Metformin continued to be used in follow-up in both groups,
with evidence of repeat prescriptions after the index date in 6403 of 8038 (80%)
glyburide users and 6660 of 8038 (83%) gliclazide users (standardized difference 8%).
Over the course of the study, there were 7913 unique health care prescribers of glyburide
or gliclazide and about 78% of prescribers were primary care physicians. Prescriptions
were filled across 477 pharmacies. Over the years of accrual, glyburide continued to be
initiated in routine care. There were 411 prescriptions in 2002 (23 per 100,000 older
adults in the general population) and 376 prescriptions in 2011 (21 per 100,000). The
initiation of gliclazide increased from less than 5 prescriptions in 2002 (at a time when
the medication was not covered under the universal prescription drug plan) to 1905
prescriptions in 2011 (106 per 100,000).

2.3.4

Metformin combination study outcomes

Prescribing glyburide was associated with a higher risk of a hospital encounter with
hypoglycemia compared with prescribing gliclazide (110 patients of 8038 taking
glyburide [1.37%] vs 19 patients of 8038 taking gliclazide [0.24%], absolute risk increase
1.13% [95% CI 0.86% to 1.40%], OR 6.06 [95% CI 3.68 to 9.97], p<0.0001). Prescribing
glyburide was also associated with a higher risk of all-cause mortality compared with
gliclazide (109 patients of 8038 taking glyburide [1.36%] vs 75 patients of 8038 taking
gliclazide [0.9%], absolute risk increase 0.43% [95% CI 0.10% to 0.76%], OR 1.47 [95%
CI 1.09 to 1.97], p=0.012) (Table 5).

2.3.5

Additional analyses

The primary outcome associations in each study proved robust in additional analyses.
Prescribing glyburide remained associated with a 90-day higher risk of a hospital
encounter with hypoglycemia compared with prescribing gliclazide after adjustment for
the year of cohort entry (monotherapy study adjusted OR 4.47 [95% CI 1.66 to 12.05],
p=0.003; metformin combination study adjusted OR 5.90 [95% CI 2.85 to 12.18],
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p<0.0001). Additionally, in time to event analyses, prescribing glyburide remained
associated with a higher risk of a hospital encounter with hypoglycemia (monotherapy
study HR 6.71 [95% CI 3.04 to 14.85], p<0.0001); metformin combination study HR
5.78 [95% CI 3.50 to 9.52], p<0.0001) (Appendix B Table 5 and 6).
In further analyses, encounters with hypoglycemia decreased throughout the study period
from 1.5% in 2002 to less than 0.5% in 2011. Encounters took place across 77 different
emergency rooms or hospitals. In the emergency room setting, day time visits (between
hours of 8AM and 8PM) were more frequent than night time visits (between hours of
8PM and 8AM) (39 vs 24 visits, respectively). Similar findings were observed in the
metformin combination study (99 different emergency rooms or hospitals, 68 day time vs
31 night time visits). When we examined total 90-day prescription costs to the provincial
drug program (in 2012 Canadian dollars), in both studies the median per patient 90-day
cost of drugs for glyburide patients was slightly less than gliclazide patients
(monotherapy study $474 vs $525, p=0.006; metformin combination study $499 vs $528,
p=0.017). Finally, when we examined the characteristics of physicians who prescribed
glyburide (vs. gliclazide), in both studies the year since medical school graduation,
physician sex, and practicing in a rural setting were not associated with prescribing
glyburide. In the monotherapy study, being a foreign (vs Canadian) trained physician was
associated with a higher likelihood of prescribing glyburide (adjusted OR 1.38 [95% CI
1.03 to 1.83]), an association not observed in the metformin combination study (adjusted
OR 1.01 [95% CI 0.87 to 1.18]).

2.4
2.4.1

Discussion
Principal findings and main implications

Despite cautionary guidelines, glyburide still continues to be initiated in older adults in
routine care.8 Yet, long-acting modified-release gliclazide is more convenient for patients
to take (once a day) than many glyburide dosing regimens. When prescribed as
monotherapy or in the presence of metformin, modified-release gliclazide is a safer
sulfonylurea than glyburide and is associated with less hypoglycemia. Although
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modified-release gliclazide has a long duration of action, its hypoglycemia risk might be
lower as it has no known active drug metabolites.27,29
At the population level, it is possible that many hospital encounters and even some deaths
may be prevented by avoiding glyburide in favor of modified-release gliclazide.
Prescription costs for glyburide and gliclazide patients were similar, and avoiding the
former could also reduce associated health care costs of hypoglycemia management.

2.4.2

Results in relation to other studies

Patients studied in randomized controlled trials typically have more regimented treatment
and monitoring than those studied in routine practice and may not include vulnerable
patient groups. In this way the findings from our population-based study extend the
results of randomized controlled trials, where the increase in risk was greater than
previous trials. In a systematic review and meta-analysis of randomized controlled trials,
glyburide was associated with a 44% greater risk (RR 1.44 [95% CI 1.13 to 1.85]) of
hypoglycemic episodes compared with other sulphonylureas (including immediate
release gliclazide, glimepiride, and chlorpropamide) across 2 studies (n=1365).30 Where
studies (n=1365) examined the risk of severe hypoglycemic events (ie. events requiring
assistance or a hospital presentation), there was no significant difference between those
prescribed glyburide vs other sulphonlyureas (RR 4.69 [95% CI 0.78 to 28.08]). In
contrast, in our population-based study the relative risk of a hospital encounter with
hypoglycemia was over 500% greater with glyburide compared with modified release
gliclazide.
Our results also extend the findings of a prior population-based study examining rates of
hypoglycemia in adult sulphonylurea users, published over 10 years ago. When glyburide
was compared with immediate release gliclazide (recognizing modified-release gliclazide
was the comparator in our study), glyburide users had a higher risk of hypoglycemia, as
assessed from the medical records of general practitioners (adjusted RR 1.35 [95% CI
1.09 to 1.69]).31
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In our metformin-glyburide combination study we also noted that glyburide vs gliclazide
was associated with a higher risk of all-cause mortality. Sulfonylurea induced
hypoglycemia has been reported to have a case-fatality rate of 4-10%.32 However, the
increased mortality in the metformin-glyburide group could have been the result of
unmeasured or incompletely quantified confounding variables.33

2.4.3

Strengths and limitations

To our knowledge our studies are the first to quantify the risk of hypoglycemia after
initiating glyburide compared with modified-release gliclazide in older adults in a real
practice setting. Compared with an older population-based study of sulphonylurea users
(noted above),31 we accounted for a number of baseline comorbidities, medications, and
measures of health care utilization including physician visits, investigations and
laboratory testing. We also excluded those on concomitant hypoglycemic agents to help
reduce confounding (apart from metformin in our combination study). Additionally, we
matched patients based on the dose equivalence of their prescription. Where a previous
study included self-reported hypoglycemia,31 in our studies, hypoglycemia was
documented in hospital records by the treating health care team.
To raise awareness, target education and quality assurance, we also illustrated trends in
glyburide use, characterized hypoglycemia encounters, explored the costs of
prescriptions, and examined the characteristics of recent glyburide prescribers. Our
research protocols, cohorts and outcomes were also prespecified, and the results were
consistent with our a priori hypotheses. Additional strengths of our 2 studies include our
examination of hypoglycemic episodes leading to hospital presentation, a more extreme
outcome in the spectrum of hypoglycemia. Such an outcome may help convince
clinicians, pharmacists and policy makers about the importance of this safety concern.
Our studies do have some limitations. Prospective data collection with independent
outcome adjudication is a preferred methodology to a retrospective database study. Also,
we assessed the outcome of a hospital encounter with hypoglycemia with administrative
codes which have limited sensitivity and accuracy compared to laboratory plasma
glucose measurements (although the latter is not the best reference standard as treatment
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with glucose has frequently been initiated in many hypoglycemic episodes by the time
plasma glucose is measured). Although episodes of hypoglycemia may be
underrepresented in our studies, we had no reason to believe they were assessed
differently in those prescribed glyburide vs gliclazide. We were also only able to
accurately ascertain medications dispensed with no information on medication use.
Additionally we were unable to capture hypoglycemic episodes experienced outside of
hospital. Further, our cost analysis was a simple calculation of the 90-day cost of all
medications to the Ontario government and we did not carry out more detailed economic
analyses.
Residual confounding is an additional consideration in all observational studies, and in
the current studies we had no information on factors such as nutrition, glucose monitoring
and patient education which may have influenced the association between sulphonylurea
type and outcome. However, using a matching technique we did obtain good balance on a
large number of measured baseline characteristics between the two groups. As well, the
magnitude of the relative risk of hypoglycemia was large in both studies and our results
proved robust in additional statistical analyses, making it unlikely that the association can
be explained entirely by confounding factors.

2.4.4

Conclusions

Although glyburide is effective in lowering blood glucose in patients with diabetes, its
use in older adults is associated with a much higher risk of hypoglycemia than modifiedrelease gliclazide. The results of our studies may help convince physicians, pharmacists
and patients who still use glyburide to consider modified-release gliclazide as a more
convenient and safer alternative.
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Table 3: Key Baseline characteristics of the monotherapy study

Glyburide
n=13,550

Unmatched
Gliclazide
n=5254

Standardized
Difference a

Glyburide
n=4374

Matched
Gliclazide
n=4374

Demographics
Age, Years*
Female*

Standardize
d Difference
a

74.52

76.10

23%

75.66

75.66

0%

6414 (47.34)

2596 (49.41)

4%

2138 (48.88)

2138 (48.88)

0%

Income based socioeconomic status b
Quintile 1 (lowest)

3189 (23.54)

1085 (20.65)

7%

994 (22.73)

881 (20.14)

6%

Rural Location

1654 (12.21)

635 (12.09)

0%

484 (11.07)

542 (12.39)

4%

Year of cohort entry c
2002

2432 (17.95)

6 (0.11)

65%

609 (13.92)

6 (0.14)

56%

2003

2640 (19.48)

18 (0.34)

68%

724 (16.55)

18 (0.41)

61%

2004

2115 (15.61)

16 (0.30)

59%

643 (14.70)

16 (0.37)

56%

2005

1754 (12.94)

23 (0.44)

52%

569 (13.01)

21 (0.48)

52%

2006

1507 (11.12)

24 (0.46)

47%

551 (12.60)

23 (0.53)

50%

2007

1061 (7.83)

996 (18.96)

33%

423 (9.67)

852 (19.48)

28%

2008

731 (5.39)

821 (15.63)

34%

309 (7.06)

696 (15.91)

28%

2009

574 (4.24)

1168 (22.23)

55%

251 (5.74)

968 (22.13)

49%

2010

419 (3.09)

1163 (22.14)

60%

163 (3.73)

935 (21.38)

55%

2011

317 (2.34)

1019(19.39)

57%

132 (3.02)

839 (19.18)

53%

Long term care

443 (3.27)

239 (4.55)

7%

165 (3.77)

197 (4.50)

4%

0 or no hospitalizations

8967 (66.18)

3088 (58.77)

15%

2648 (60.54)

2665 (60.93)

1%

1

1585 (11.70)

743 (14.14)

7%

576 (13.17)

589 (13.47)

1%

2

1344 (9.92)

594 (11.31)

5%

501 (11.45)

481 (11.00)

1%

≥3

1654 (12.21)

829 (15.78)

10%

649 (14.84)

639 (14.61)

1%

Charlson Comorbidity Index d

Health care visits in the prior year
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Cardiologist visit *

4476 (33.03)

2181 (41.51)

18%

1724 (39.41)

1739 (39.76)

1%

Ophthalmologist visit

3614 (26.67)

1588 (30.22)

8%

1331 (30.43)

1275 (29.15)

3%

Endocrinologist visit*
Internist visit

767 (5.66)

465 (8.85)

12%

363 (8.30)

363 (8.30)

0%

2936 (21.67)

1414 (26.91)

12%

1101 (25.17)

1150 (26.29)

3%

Sulphonylurea prescriber
General practitioner

10,393 (76.70)

4152 (79.03)

6%

3398 (77.69)

3474 (79.42)

4%

Internist

208 (1.54)

144 (2.74)

8%

78 (1.78)

119 (2.72)

8%

Endocrinologist

149 (1.10)

161 (3.06)

14%

66 (1.51)

118 (2.70)

8%

Other

836 (6.17)

259 (4.93)

5%

272 (6.22)

221 (5.05)

5%

1961 (14.47)

535 (10.18)

13%

560 (12.80)

439 (10.04)

9%

Chronic kidney disease* f

1010 (7.45)

886 (16.86)

29%

601 (13.74)

601 (13.74)

0%

Congestive heart failure*

2055 (15.17)

969 (18.44)

9%

722 (16.51)

758 (17.33)

2%

1118 (8.25)

514 (9.78)

5%

431 (9.85)

420 (9.60)

1%

1638 (12.09)

804 (15.30)

9%

655 (14.97)

650 (14.86)

0%

Missing
Comorbidities

e

Thyroid disease

g

Investigations h
Carotid ultrasound
Coronary angiogram

885 (6.53)

498 (9.48)

11%

371 (8.48)

403 (9.21)

3%

Coronary revascularization

537 (3.96)

262 (4.99)

5%

240 (5.49)

210 (4.80)

3%

Echocardiography*

4379 (32.32)

2334 (44.42)

25%

1853 (42.36)

1851 (42.32)

0%

Holter monitoring*

1744 (12.87)

1025 (19.51)

18%

772 (17.65)

805 (18.40)

2%

Stress test

3753 (27.70)

1845 (35.12)

16%

1506 (34.43)

1491 (34.09)

1%

At least one HbA1c test*

10208 (75.34)

4738 (90.18)

40%

3895 (89.05)

3876 (88.61)

1%

Diabetes management * i

629 (4.64)

1122 (21.36)

51%

485 (11.09)

582 (13.31)

7%

Diabetes incentive* j

413 (3.05)

1028 (19.57)

54%

336 (7.68)

455 (10.40)

9%

ACE inhibitors

4287 (31.64)

1813 (34.51)

6%

1551 (35.46)

1503 (34.36)

2%

ARBs*

1482 (10.94)

1281 (24.38)

36%

891 (20.37)

904 (20.67)

1%

Antidepressants*

1466 (10.82)

815 (15.51)

14%

612 (13.99)

629 (14.38)

1%

Beta blockers

3428 (25.30)

1733 (32.98)

17%

1341 (30.66)

1346 (30.77)

0%

Medications k
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Corticosteroids*
Ezetimibe*
Glucose test strips*

2575 (19.00)

1000 (19.03)

0%

794 (18.15)

823 (18.82)

2%

131 (0.97)

280 (5.33)

25%

100 (2.29)

122 (2.79)

3%

20 (0.15)

164 (3.12)

24%

16 (0.37)

20 (0.46)

1%

H2 Receptor Antagonists*

1083 (7.99)

219 (4.17)

16%

207 (4.73)

238 (5.44)

3%

Loop diuretics

1790 (13.21)

913 (17.38)

12%

686 (15.68)

688 (15.73)

0%

Potassium sparing
diuretics
Statins*

867 (6.40)

350 (6.66)

1%

299 (6.84)

279 (6.38)

2%

4155 (30.66)

2730 (51.96)

44%

2044 (46.73)

2094 (47.87)

2%

Thiazide diuretics

2040 (15.06)

939 (17.87)

8%

747 (17.08)

742 (16.96)

0%

Thyroid replacement*

1291 (9.53)

763 (14.52)

15%

553 (12.64)

582 (13.31)

2%

1

8496 (62.70)

3905 (74.32)

25%

3246 (74.21)

3246 (74.21)

0%

2

3649 (26.93)

982 (18.69)

20%

899 (20.55)

899 (20.55)

0%

3

343 (2.53)

123 (2.34)

1%

96 (2.19)

96 (2.19)

0%

4

857 (6.32)

152 (2.89)

16%

133 (3.04)

133 (3.04)

0%

Drug Dosage

l

Laboratory Data

m

Evidence of creatinine
value
Mean creatinine (umol/L)
(SD)
Median creatinine
(umol/L) (IQR)
Mean GFR (mL/min/1.73
m2) (SD)
Median GFR
(mL/min/1.73 m2) (IQR)
Evidence of HbA1c value

2505 (18.49)

1373 (26.13)

18%

896 (20.48)

1108 (25.33)

12%

93.25 (38.55)

103.89 (47.14)

25%

97.54 (40.74)

100.71 (46.81)

7%

83.71 (69.32105.76)
67.78 (19.82)

93.29 (74.12-123.02)

--36%

90.42 (72.20117.13)
62.29 (20.61)

---

60.33 (21.72)

85.81 (72.20111.51)
64.75 (20.49)

70.83 (54.4983.91)
1639 (12.10)

60.47 (43.86-78.40)

---

1096 (20.86)

24%

67.27 (48.8582.04)
641 (14.65)

63.21 (46.4680.61)
877 (20.05)

14%

12%
---

Mean HbA1c (SD)

0.079 (0.019)

0.075 (0.015)

22%

0.077 (0.018)

0.075 (0.015)

15%

Median HbA1c (IQR)

0.074 (0.0660.086)

0.072 (0.066-0.080)

---

0.073 (0.0660.083)

0.072 (0.0650.080)

---

Data presented as number (percent) except where indicated.
Cell sizes less than six were not reported for reasons of privacy.
Abbreviations: ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, IQR interquartile range, GFR glomerular
filtration rate, SD standard deviation.
Variables marked * were included as covariates in the propensity score model.
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a
Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the
pooled standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups.
b
Income was categorized into fifths of average neighborhood income on the index date.
c
The year of cohort entry is also referred to as the index date.
34
d
Charlson Comorbidity Index was calculated using five years of hospitalization data. “No hospitalizations” received a score of 0.
e
Comorbidities were assessed by administrative database codes in the previous five years.
Less than 5% had evidence of a nephrologist visit in the one year prior or evidence of alcoholism, chronic liver disease, peripheral vascular disease, sepsis or pancreatitis
in the five years prior. Less than 1% had evidence of pituitary disease, adrenal disease, pancreatic cancer or diabetic retinopathy in the five years prior.
f
We identified individuals with chronic kidney disease using a validated algorithm of diagnosis and physician claim codes. In Ontario, this algorithm identifies patients
with a median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52). Its absence identifies patients with a median eGFR of
35
69 mL/min per 1.73 m2 (interquartile range 56 to 82).
g
Thyroid disease includes hypothyroidism, thyroiditis, iodine deficiency related thyroid disorders, nontoxic goiter, thyrotoxicosis, and other disorders of the thyroid.
h
Investigations were assessed by administrative codes in the previous five years.
i
Diabetes management is an all-inclusive service payable to the most responsible physician for providing continuing management and support of a diabetic patient. The
service must include assessments focusing on diabetic target organ systems, relevant counseling and maintenance of a diabetic flow sheet retained on the patient’s
permanent medical record. The flow sheet must track lipids, cholesterol, HbA1C, urinalysis, blood pressure, fundal examination, peripheral vascular examination,
36
weight, body mass index and medication dosage.
j
Diabetes management incentive is a fee rendered to a general practitioner providing ongoing management of a diabetic patient consistent with the requirements of the
Canadian Diabetes Association including a minimum of lipid, HbA1C, blood pressure, body mass index measurement, albumin:creatinine, preventative measures and
36
health promotion, referral for dilated eye exam, foot and neurological exam over the previous 12 months.
k
Baseline medication use was assessed in the previous 120 days.
Less than 5% received prescriptions for atypical antipsychotics, amiodarone, clarithromycin, fibrates, gatifloxacin or sulphonamides. Less than 1% received prescriptions
for valproic acid, protease inhibitors, monoamine oxidase inhibitors, danazol, isoniazid, disopyramine, tacrolimus/sirolimus, probenicid, rifampin, aliskerin, androgens,
barbiturates, carbamazepine, clonidine, cyclosporine, fluconazole/voriconazole, tetracycline. There were no prescriptions for acetohexamide, chloramphenicol,
pegvisimont, colesevelam, reserpine, guanethidine, ifosfamide, phenylbutazone, diazoxide, aprepitant and bosentan.
l
Drug dose level 1=glyburide 5mg/modified release gliclazide 30mg, 2=glyburide 10mg/ modified release gliclazide 60mg, 3=glyburide 15mg/ modified release
gliclazide 90 mg, 4=glyburide 20mg/modified release gliclazide 120 mg.
m
Where available, laboratory data was collected in the one year previous.

45

Table 4: Key baseline characteristics the metformin combination study
Unmatched

Matched

Gliclazide
n=9967

Standardized
Difference a

73.12

73.58

8%

73.34

73.33

7952 (47.81)

4572 (45.87)

4%

3707 (46.12)

3707 (46.12)

0%

3931 (23.64)

2080 (20.87)

7%

1793 (22.31)

1715 (21.34)

2%

2036 (12.24)

1247 (12.51)

1%

1031 (12.83)

997 (12.40)

1%

2002

1191 (7.16)

<=5 (0.05)

39%

411 (5.11)

<=5 (<=0.06)

--

2003

1910 (11.48)

8 (0.08)

50%

743 (9.24)

7 (0.09)

44%

2004

2202 (13.24)

15 (0.15)

54%

930 (11.57)

14 (0.17)

50%

2005

2280 (13.71)

18 (0.18)

55%

1050 (13.06)

18 (0.22)

53%

2006

2585 (15.54)

34 (0.34)

59%

1306 (16.25)

29 (0.36)

60%

2007

2070 (12.45)

1013 (10.16)

7%

1137 (14.15)

873 (10.86)

10%

2008

1460 (8.78)

1386 (13.91)

16%

777 (9.67)

1161 (14.44)

15%

2009

1218 (7.32)

2163 (21.70)

42%

722 (8.98)

1754 (21.82)

36%

2010

1036 (6.23)

2904 (29.14)

63%

586 (7.29)

2275 (28.30)

57%

2011

679 (4.08)

2424 (24.32)

61%

376 (4.68)

1905 (23.70)

57%

Long term care

268 (1.61)

173 (1.74)

1%

120 (1.49)

144 (1.79)

2%

11,164
(67.13)
2150 (12.93)

5857 (58.76)

17%

5146 (64.02)

4902 (60.99)

6%

1682 (16.88)

11%

1137 (14.15)

1281 (15.94)

5%

2

1575 (9.47)

1063 (10.67)

4%

844 (10.50)

808 (10.05)

1%

≥3

1742 (10.47)

1365 (13.70)

10%

911 (11.33)

1047 (13.03)

5%

3685 (36.97)

10%

2849 (35.44)

2900 (36.08)

1%

Glyburide
n=16,631

Glyburide
n=8038

Gliclazide
n=8038

Standardized
Difference a

Demographics
Age, years*
Female*

0%

Income based socioeconomic status b
Quintile 1 (lowest)
Rural location
Year of cohort entry

c

Charlson Comorbidity Index
0 or no hospitalizations
1

d

Health care visits in the year prior
Cardiologist visit *

5397 (32.45)
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Ophthalmologist visit

4469 (26.87)

2956 (29.66)

6%

2392 (29.76)

2298 (28.59)

3%

Endocrinologist visit *

1072 (6.45)

884 (8.87)

9%

696 (8.66)

696 (8.66)

0%

Internist visit *

3440 (20.68)

2564 (25.72)

12%

1972 (24.53)

1992 (24.78)

1%

7862 (78.88)

3%

6248 (77.73)

6343 (78.91)

3%

Endocrinologist

12,894
(77.53)
353 (2.12)

398 (3.99)

11%

181 (2.25)

294 (3.66)

8%

Internist

296 (1.78)

296 (2.97)

8%

154 (1.92)

244 (3.04)

7%

Sulphonylurea prescriber
General practitioner

Other
Missing

771 (4.64)

384 (3.85)

4%

344 (4.28)

318 (3.96)

2%

2347 (14.11)

1024 (10.28)

12%

1111 (13.82)

837 (10.41)

10%

Comorbidities e
Chronic kidney
disease* f heart
Congestive

723 (4.35)

640 (6.42)

9%

420 (5.23)

420 (5.23)

0%

1805 (10.85)

1026 (10.29)

2%

813 (10.11)

810 (10.08)

0%

failure*
Thyroid disease g

1193 (7.17)

711 (7.13)

0%

610 (7.59)

557 (6.93)

3%

Carotid ultrasound

1924 (11.57)

1433 (14.38)

8%

1072 (13.34)

1114 (13.86)

2%

Coronary angiogram

1247 (7.50)

935 (9.38)

7%

763 (9.49)

714 (8.88)

2%

Coronary
revascularization
Echocardiography*

737 (4.43)

540 (5.42)

5%

458 (5.70)

400 (4.98)

3%

5368 (32.28)

4150 (41.64)

19%

3172 (39.46)

3182 (39.59)

0%

Holter monitoring*

2063 (12.40)

1611 (16.16)

11%

1214 (15.10)

1238 (15.40)

1%

Stress test

4943 (29.72)

3625 (36.37)

14%

2832 (35.23)

2805 (34.90)

1%

At least 1 HbA1c test *

14431
(86.77)
2023 (12.16)

9317 (93.48)

23%

7474 (92.98)

7416 (92.62)

3%

3275 (32.86)

51%

1698 (21.12)

1905 (23.70)

6%

1382 (8.30)

2952 (29.60)

60%

1245 (15.49)

1496 (18.61)

8%

ACE inhibitors

6403 (38.50)

4085 (40.99)

5%

3464 (43.10)

3225 (40.12)

6%

ARBs*

2644 (15.90)

2641 (26.50)

26%

1854 (23.07)

1876 (23.34)

1%

Antidepressants*

1778 (10.69)

1289 (12.93)

7%

971 (12.08)

1002 (12.47)

1%

Beta blockers

4166 (25.05)

2951 (29.61)

10%

2405 (29.92)

2244 (27.92)

4%

Corticosteroids*

2583 (15.53)

1582 (15.87)

1%

1264 (15.73)

1272 (15.82)

0%

Investigations h

Diabetes management
*i
Diabetes
incentive* j
Medications k
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Clonidine

38 (0.23)

20 (0.20)

1%

22 (0.27)

14 (0.17)

2%

Ezetimibe*

243 (1.46)

563 (5.65)

23%

218 (2.71)

266 (3.31)

3%

Glucose test strips*

78 (0.47)

223 (2.24)

15%

74 (0.92)

99 (1.23)

3%

H2 receptor blockers*

992 (5.96)

357 (3.58)

11%

318 (3.96)

355 (4.42)

2%

Loop diuretics

1486 (8.94)

885 (8.88)

0%

745 (9.27)

677 (8.42)

3%

Potassium sparing
diuretics
Statins*

734 (4.41)

414 (4.15)

1%

362 (4.50)

318 (3.96)

3%

7089 (42.63)

6112 (61.32)

38%

4635 (57.66)

4589 (57.09)

1%

Thiazide diuretics*

2865 (17.23)

1868 (18.74)

4%

1484 (18.46)

1473 (18.33)

0%

Thyroid replacement*

1597 (9.60)

1154 (11.58)

6%

866 (10.77)

866 (10.77)

0%

1

8430 (50.69)

7212 (72.36)

46%

5620 (69.92)

5620 (69.92)

0%

2

5707 (34.32)

2038 (20.45)

31%

1908 (23.74)

1908 (23.74)

0%

3

459 (2.76)

217 (2.18)

4%

169 (2.10)

169 (2.10)

0%

4

1895 (11.39)

377 (3.78)

29%

341 (4.24)

341 (4.24)

0%

3645 (21.92)

2688 (26.97)

12%

1954 (24.31)

2138 (26.60)

5%

84.83 (27.58)

87.22 (30.53)

8%

85.34 (27.31)

86.57 (29.74)

4%

79.87 (67.4195.21)
72.23 (17.73)

81.79 (68.37-97.13)

--7%

80.83 (68.0096.17)
71.53 (18.37)

---

70.99 (18.48)

79.87 (67.4195.21)
71.87 (17.71)

74.93 (60.4186.96)
3333 (20.04)

74.08 (59.13-86.19)

---

2484 (24.92)

12%

74.13 (59.8586.78)
1836 (22.84)

74.92 (59.9186.43)
1960 (24.38)

4%

0.083 (0.020)

0.080 (0.018)

14%

0.081 (0.018)

0.081 (0.019)

2%

Drug Dosage l

Laboratory Data m
Serum creatinine value
available
Mean creatinine
(umol/L) (SD)
Median creatinine
(umol/L) (IQR)
Mean GFR
(mL/min/1.73 m2)
Median (mL/min/1.73
m2) (IQR)
HbA1c value available
Mean HbA1c (SD)
Median HbA1c (IQR)

2%
---

0.078 (0.070- 0.076 (0.070-0.085)
0.076 (0.0690.076 (0.0700.092)
0.087)
0.087)
Data presented as number (percent) except where indicated.
Cell sizes less than 6 were not reported for reasons of privacy.
Abbreviations: ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, HbA1c glycosylated hemoglobin, IQR interquartile range, GFR glomerular filtration rate,
SD standard deviation.
Variables marked * were included as covariates in the propensity score.
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a

Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups divided by the pooled standard
deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups.
b
Income was categorized into fifths of average neighborhood income on the index date.
c
The year of cohort entry is also referred to as the index date.
34
d
Charlson Comorbidity Index was calculated using five years of hospitalization data. “No hospitalizations” received a score of 0.
e
Comorbidities were assessed by administrative database codes in the previous five years.
Less than 5% had evidence of a nephrologist visit in the one year prior or evidence of chronic liver disease, peripheral vascular disease or sepsis in the five years prior. Less than 1%
had evidence of alcoholism, diabetic retinopathy, pituitary disease, adrenal disease, pancreatitis, pancreatectomy or pancreatic cancer in the five years prior.
f
We identified individuals with chronic kidney disease using a validated algorithm of diagnosis and physician claim codes. In Ontario, this algorithm identifies patients with a
median estimated glomerular filtration rate (eGFR) of 38 mL/min per 1.73 m2 (interquartile range 27 to 52). Its absence identifies patients with a median eGFR of 69 mL/min per
35
1.73 m2 (interquartile range 56 to 82).
g
Thyroid disease includes hypothyroidism, thyroiditis, iodine deficiency related thyroid disorders, nontoxic goiter, thyrotoxicosis, and other disorders of the thyroid.
h
Investigations were assessed by administrative codes in the previous five years.
i
Diabetes management is an all-inclusive service payable to the most responsible physician for providing continuing management and support of a diabetic patient. The service must
include assessments focusing on diabetic target organ systems, relevant counseling and maintenance of a diabetic flow sheet retained on the patient’s permanent medical record. The
36
flow sheet must track lipids, cholesterol, HbA1C, urinalysis, blood pressure, fundal examination, peripheral vascular examination, weight, body mass index and medication dosage.
j
Diabetes management incentive is a fee rendered to a general practitioner providing ongoing management of a diabetic patient consistent with the requirements of the Canadian
Diabetes Association including a minimum of lipid, HbA1C, blood pressure, body mass index measurement, albumin:creatinine, preventative measures and health promotion, referral
36
for dilated eye exam, foot and neurological exam over the previous 12 months.
k
Baseline medication use was assessed in the previous 120 days.
Less than 5% received prescriptions for atypical antipsychotics, clarithyromycin, fibrates, gatifloxacin or sulphonamides. Less than 1% received prescriptions for
tacrolimus/sirolimus chloramphenicol, cyclosporine, disopyramine, isoniazid, probenicid, rifampin, aprepitant, protease inhibitors, danazol, valproic acid, monoamine oxidase
inhibitors, aliskerin, amiodarone, androgens, barbiturates, carbamazepine, clonidine, fluconazole/voriconazole or tetracycline. There were no prescriptions for acetohexamide,
pegvisimont, colesevelam, reserpine, guanethidine, ifosfamide, phenylbutazone, diazoxide or bosentan.
l
Drug dose level 1=glyburide 5mg/modified release gliclazide 30mg, 2=glyburide 10mg/ modified release gliclazide 60mg, 3=glyburide 15mg/ modified release gliclazide 90 mg,
4=glyburide 20mg/modified release gliclazide 120 mg.
m
Where available, laboratory data was collected in the 1 year previous.
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Table 5: Ninety-day outcomes in the monotherapy study
Number of Events (%)
Risk
Difference
Glyburide
Gliclazide
(%) (95% CI)
n=4374
n=4374

NNH (95%
CI)

Conditional
OR (95% CI)

p-value

Hospital
encounter with
hypoglycemia

69 (1.58%)

8 (0.18%)

1.40% (1.01%
to 1.79%)

71 (55 to 99) 8.63 (4.15 to
17.93)

<0.0001

All-cause
mortality

100 (2.29%)

84 (1.92%)

0.37% (-0.21%
to 0.95%)

(…)

0.22

Patients prescribed gliclazide served as the referent group.
Abbreviations: NNH Number needed to harm
(…) NNH not significant.

1.21 (0.89 to
1.63)
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Table 6: Ninety-day outcomes in the metformin combination study
Number of Events (%)
Glyburide
n=8038

Gliclazide
n=8038

Risk Difference
(%) (95% CI)

NNH (95%
CI)

Conditional
OR (95%
CI)

p-value

Hospital encounter 110 (1.37%)
with hypoglycemia

19 (0.24%)

1.13% (0.86% to
1.40%)

77 (71 to 116)

6.06 (3.68 to
9.97)

<0.0001

All-cause mortality 109 (1.36%)

75 (0.93%)

0.43% (0.10% to
0.76%)

233 (131 to
1000)

1.47 (1.09 to
1.97)

0.012

Patients prescribed gliclazide served as the referent group
Abbreviations: NNH Number needed to harm
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Trends in antihyperglycemic medication prescriptions and
hypoglycemia in older adults: 2002-2013

Kristin K Clemens, MD 1; Salimah Shariff, PhD 2; Kuan Liu, MMath 2; Irene Hramiak, MD 3;
Jeffrey L Mahon, MD 3,4; Eric McArthur, MSc 2 ; Amit X. Garg, MD PhD 1,2,4
1. Department of Medicine, Western University, London Ontario Canada
2. Institute for Clinical Evaluative Sciences, London Ontario Canada
3. Department of Medicine, Division of Endocrinology, Western University, London Ontario
Canada
4. Department of Epidemiology and Biostatistics, Western University, London Ontario Canada

3.1 Introduction
The management of glycemic control in older patients with type 2 diabetes has become
increasingly complex over the last decade.1 First, where only sulfonylureas (eg. glyburide),
insulin, alpha glucosidase inhibitors (eg. acarbose), and biguanides (eg. metformin) were
accessible in Canada in the 1990’s, there are now 9 classes of medications and at least 20 unique
drugs and their combinations available to control hyperglycemia. Second, while all drugs by
design lower glucose levels, there are important differences among them with respect to their
other known or suspected advantages and risks. Of particular importance in older patients are
differences among the medications in risk for hypoglycemia.2–4 Third, while randomized trials
have established the benefit of intensified glycemic control in reducing risk for microvascular
complications, it remains unclear as to whether this also leads to an important reduction in risk
for macrovascular complications and, if so, whether such benefit exceeds the risks of tighter
control in all cases.5,6
Given that there are limited data on how antihyperglycemic medications are being used in older
patients with diabetes, in the current study we aimed to examine patterns in antihyperglycemic
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medication prescriptions in this population from 2002 until 2013. As the hypoglycemia risk of
these medications differ, we also examined their hospital encounters for hypoglycemia over the
period of study.

3.2
3.2.1

Methods
Study design and setting

We conducted population-based cross sectional analyses of older adults with diabetes from April
1, 2002 until March 31, 2013, using linked health care databases in Ontario Canada. Ontario
currently has a population of over 13 million people, of which 2 million are age 65 years or
older.7 In our province, people over the age of 65 have universal coverage for outpatient
prescription medications, physician services, hospitalizations and investigations.8
Databases were linked using unique, encoded identifiers and were analyzed at the Institute for
Clinical Evaluative Sciences according to a pre-specified protocol. The study was approved by
the research ethics board at Sunnybrook Health Sciences Centre (Toronto, Canada). Participant
informed consent was not required.
We divided our study timeframe into 3-month intervals (study quarters). We report this study
using guidelines for observational studies (checklist of recommendations presented in Appendix
D Table 1).9

3.2.2

Data sources

We used 6 databases to examine patient characteristics, drug use, covariate information, and
outcomes. To identify patients with diabetes, we used the Ontario Diabetes Database (ODD), a
previously validated electronic registry with 86% sensitivity and 97% specificity to detect
diabetes.10 The Registered Persons Database of Ontario was used to collect vital statistics. It
contains demographic information for all Ontario residents who have ever been issued a health
card. We used the Ontario Drug Benefit Program database to examine prescription medications
as in our province, adults age 65 and older are eligible for drug coverage, and the information on
these prescribed medications is accurately contained within this database (error rate of less than
1%).11 Diagnostic and procedural information on hospitalizations and emergency room visits was
obtained from the Canadian Institute for Health Information’s Discharge Abstract Database and
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the National Ambulatory Care Reporting System database. We obtained additional covariate
information from the Ontario Health Insurance Plan database, which includes health claims for
inpatient and outpatient physician services. A subpopulation had outpatient glycosylated
hemoglobin (HbA1c) values available in the 1 year prior to the relevant study quarter.
International Classification of Diseases 9th revision (ICD-9, pre-2002), 10th Revision (ICD-10,
post-2002), Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures (CCP,
pre-2002) and Canadian Classification of Health Interventions (CCI, post-2002) codes were used
to assess baseline comorbidities in the 5 years prior to 3 study quarters (administrative codes
listed in Appendix D Table 2). Codes utilized to ascertain hypoglycemia encounters are detailed
in Appendix D Table 3, which lists only ICD-10 codes as all events would have occurred after
the implementation of this coding system in Canada.

3.2.3

Patients

During each quarter, we identified all adults with diabetes as defined by the ODD. We then
excluded the following patients from analysis: 1) those with a missing age or sex, invalid age
(over 105 years) or death recorded on or before the beginning of the quarter (for data cleaning
purposes), 2) non-Ontarian residents at the beginning of each quarter (to allow for adequate
patient follow-up), and 3) those under the age of 66 (as the province’s drug formulary provides
prescription coverage to those over the age of 65 and to avoid incomplete medication records in
their first year of eligibility).
We defined patients with treated diabetes as those who had evidence of at least 1
antihyperglycemic prescription (including insulin or an oral antihyperglycemic medication)
during the study quarter, insulin users as those with evidence of at least 1 prescription for insulin
during the study quarter, and patients with newly treated diabetes as those who had evidence of
at least 1 antihyperglycemic medication prescription during the quarter with no evidence of a
previous prescription for any agent in the 1 year prior. Monotherapy users had evidence of only 1
antihyperglycemic medication prescription during the relevant quarter and combination users had
evidence of more than 1 prescription.
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3.2.4

Outcomes

For the primary outcome, we examined the percentage of treated and newly treated patients with
a prescription for insulin, sulphonylureas, alpha-glucosidase inhibitors, metformin,
thiazolidinediones, meglitinides, and dipeptidyl peptidase-4 inhibitors (DPP-4). These
antihyperglycemic medications are the only agents currently covered by our provincial drug
formulary. For our secondary outcome we examined the percentage of treated patients with a
hospital encounter with hypoglycemia (emergency room visit or inpatient admission) during
each quarter of study.

3.2.5

Statistical analysis

We used descriptive statistics to summarize the baseline characteristics of patients with treated
and newly treated diabetes at the beginning of three study quarters (April 1 2002, April 1, 2007,
April 1, 2012). The percentage of patients prescribed each antihyperglycemic medication during
the relevant quarter was calculated by dividing the total number with a prescription (numerator)
by the total number of treated patients (or newly treated patients) (denominator) during the
quarter. The percentage of patients with a hypoglycemia encounter during each quarter was
determined by dividing the total number of patients with at least 1 encounter (numerator) by the
total number of treated patients (denominator). We conducted all analyses with SAS version 9.3
(SAS Institute, Cary, North Carolina).

3.3

Results

Over the decade from April 2002 until March 2013, the number of patients with treated diabetes
almost doubled from 148,021 to 289,312 individuals (Figure 1). The baseline characteristics of
treated and newly treated patients are presented in Table 7 and Appendix D Table 4 respectively.
In both groups, their mean age remained stable over the study quarters as did the proportion that
were female. With the exception of chronic kidney disease, the percentage with a diabetesrelated comorbidity appeared to decline. Where available for a sub-population of included
patients, HbA1c values appeared to increase slightly (Table 7 and Appendix D Table 4).
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3.3.1

Patients with treated diabetes

Figure 2 shows the percentage of patients with treated diabetes with a prescription for insulin,
sulphonylureas, alpha-glucosidase inhibitors, metformin, meglitinides, thiazolidinediones and
DPP-4 inhibitors from 2002 until 2013.
The percentage prescribed metformin increased over the study period (56.17% in first quarter,
76.51% in last quarter), as did prescriptions for the DPP-4 inhibitors saxagliptin (prescriptions
increased from 0% to 1.79% following its formulary introduction in 2012) and sitagliptin
(prescriptions increased from 0% to 18.09% following its formulary introduction in 2010). A
decline in glyburide prescriptions was evident (56.43% in the first quarter, 10.65% in the last
quarter), while gliclazide prescriptions increased (prescriptions increased from 0.40% to 24.30%
following the formulary introduction of modified-release gliclazide in 2007). Over the last 10
years about 20% of treated patients have been prescribed insulin. Further, after an initial increase
following their introduction to the provincial formulary in 2006/2007, thiazolidinedione
prescriptions declined, although pioglitazone did so less steeply than rosiglitazone. Prescriptions
for acarbose, acetohexamide, glimepiride, repaglinide, tolbutamide, nateglinide, and
chlorpropamide have remained low (less than 5% of patients had evidence of a prescription
during each study quarter).
Antihyperglycemic mono and combination therapy is illustrated in Appendix D Figure 1 and 2.
Over the last decade, there was a small decrease in the percentage of patients prescribed
monotherapy (including insulin monotherapy), and a small increase in those prescribed three or
more agents (including in insulin users). The oral antihyperglycemic medications prescribed in
insulin users are illustrated in Appendix D Figure 3.

3.3.2

Patients with newly treated diabetes

New antihyperglycemic medication prescriptions are illustrated in Appendix D Figure 4. The
majority of patients were prescribed metformin (approximately 80%), with a small percentage
decrease noted from July 2006 until April 2008. The percentage of patients prescribed the DPP-4
inhibitors increased (prescriptions for sitagliptin increased from 0% to 10.10% following its
introduction to the formulary; saxagliptin prescriptions increased from 0% to 2.08% following its
introduction to the formulary). We also note that fewer of these patients were initiated on
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glyburide over time, (38.99% in the first quarter and 2.90% in the last quarter) with an increasing
number initiated on gliclazide (prescriptions increased from 0.26% to 11.69% following the
introduction of modified-release gliclazide to the formulary). Insulin use remained relatively
stable (approximately 7%). Further, although thiazolidinedione prescriptions initially rose in
2006/2007, they have since decreased. Prescriptions for acarbose, acetohexamide, glimepiride,
repaglinide, tolbutamide, nateglinide, and chlorpropamide remained low (less than 5% of
patients had evidence of a prescription during each study quarter).
Where mono- and combination therapy was examined in newly treated patients, there was a
slight decrease in monotherapy (including insulin monotherapy) and an increase in combination
therapy over time (including insulin combination therapy) (Appendix D Figure 5 and 6).

3.3.3

Hypoglycemia

In the setting of these prescription trends, the absolute number of treated patients with a
hypoglycemia encounter increased until mid-2006 and then declined. However, when the
increasing prevalence of treated diabetes was accounted for, the percentage with a hospital
encounter with hypoglycemia declined by 50% over the decade (0.79% with an event in the first
quarter, 0.41% with an event in the last quarter). (Figure 3)

3.4
3.4.1

Discussion
Principal findings and main implications

In this study we have identified several trends in antihyperglycemic medication prescriptions in
patients with diabetes age 66 and older in Ontario.
First, over the last decade there has been a substantial increase in the number of older adults
using antihyperglycemic medications in our province. Whether this increase is due to an
increased detection of diabetes, an aging population, or a higher number of individuals with
obesity and sedentary lifestyle remains to be determined.
Second, consistent with guidelines which recommend metformin as a first line agent for its
efficacy, safety, weight effects, and possible cardiovascular benefit,12,13 metformin remains the
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most commonly prescribed antihyperglycemic medication among older adults in Ontario. This
result is consistent with high rates of metformin use in other jurisdictions.14–18
Third, we found that prescriptions for glyburide steadily declined over the last decade whereas
those for gliclazide have increased. This change is consistent with clinical practice guidelines
which have endorsed avoiding glyburide in older patients in favour of sulphonylureas including
gliclazide that have a lower risk for hypoglycemia. 19
Fourth, since their addition to the drug formulary, prescriptions for both pioglitazone and
rosiglitazone have declined. These findings may reflect safety concerns that have arisen with
these medications,20–23 regulatory advisories (Appendix D Table 5), and funding status changes
in our province (thiazolidinediones transferred from the unrestricted formulary to the exceptional
access program in in June 2009). 24,25 Pioglitazone currently remains more commonly prescribed
than rosiglitazone perhaps reflecting evidence of its better safety profile compared with its
counterpart.26–28 Consistent with the findings of research in other regions, we also note that there
has been an uptake of new medications including the DPP-4 inhibitors.14,17,18
Fifth, we found that that combination therapy has increased over time, including in newly treated
patients. It is possible that clinical trials that have suggested the benefit of intensive glycemic
control in the prevention of microvascular complications have been contributory,5,6 along with
the possibility of personalizing therapy with several drugs in order to achieve better control.16
Further, published reports have noted that combination therapy at submaximal doses may help to
improve glycemic control more rapidly and with fewer side effects than monotherapy,13,29–31 and
practice guidelines suggest that combination therapy be initiated in patients with higher
HbA1c’s.13
Finally, in the setting of these prescription trends, the overall percentage of treated patients with
a hospital encounter for hypoglycemia has declined in our region. Our findings are consistent
with a recent study of United States Medicare beneficiaries (1999 to 2011). When the changing
prevalence of diabetes was accounted for by the authors, admissions for hypoglycemia decreased
by 9.5%.32 Although a decline in the use of glyburide and the uptake of agents associated with a
lower hypoglycemic risk may have contributed to this trend, other factors including changes in
the accuracy of diagnostic coding, diabetes screening, quality of patient care and education, 33
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secular trends in glycemic control, and the characteristics of patients with the disease
(comorbidities, functional limitations, self-management behavior), may have also played a role.
32,34

3.4.2

Strengths and limitations

Compared with previous drug trend studies, our report has several strengths.18,24,25,27 First, we
comprehensively examined all 15 antihyperglycemic medications currently covered by the
provincial drug formulary and ascertained prescription trends in a variety of antihyperglycemic
medication users (including those with treated and newly treated diabetes). Our decade of study
also allowed for an assessment of medication trends during an era of changing diabetes care.
Where previous studies have been limited to younger patients with diabetes, ours provided a
perspective on prescribing practices in a more vulnerable population of older adults. We also
detailed the demographic characteristics, comorbidities, and HbA1c values of included patients
to help put prescribing practices into context. Finally, in the setting of changing prescription
trends, we quantified both inpatient and emergency room hospital encounters with hypoglycemia
– a serious adverse event in older patients.
Our study has limitations. We were unable to capture antihyperglycemic medication
prescriptions not covered by our provincial formulary (including glucagon like peptide-1
agonists and sodium glucose co-transporter 2 inhibitors). Although we expect our results to be
generalizable to the elderly with publically funded healthcare, we cannot extend our results to
those under the age of 65 or on other drug funding schemes where variations in drug prescribing
have been noted.
Our databases also did not allow us to evaluate diabetes type, although given their age and the
prevalence of type 2 diabetes, the majority of patients may have had type 2 diabetes. Further, we
could not capture their duration of diabetes which can influence treatment choices and diabetesrelated complications.34
For our outcome of hypoglycemia, we were unable to assess events experienced outside of the
hospital, including emergency medical service contacts or home events that did not lead to
hospital presentation. Additionally, we assessed the outcome of hypoglycemia with
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administrative codes which have limited sensitivity when compared to laboratory plasma glucose
measurements (although the latter is not the best reference standard as treatment with glucose
may have been initiated by the time plasma glucose is measured). Further, although we do note a
decline in the use of glyburide and the uptake of safer medications, these data do not prove that
prescription changes led to a decline in the rates of hypoglycemia. Although we did measure
comorbidities and demographic characteristics that are associated with hypoglycemia, we were
also unable to account for changes in health literacy, attitudes, and social support which could
cause differences in the likelihood of seeking medical care.33

3.4.3

Conclusions

Antihyperglycemic medication prescribing practices have changed significantly in Ontario over
the last 11 years. In the setting of a decline in the use of glyburide, and the uptake of drugs with a
lower hypoglycemia risk, there has been a decrease in the percentage of treated patients with a
hospital encounter for hypoglycemia in our region. The extent to which this reduction is related
to the use of safer medication or to other factors remains to be established.
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Table 7. Baseline characteristics of patients with treated diabetes
April 1, 2002
N= 148,021

%

April 1, 2007
N=212,538

%

April 1, 2012
N=288,866

%

Age (yr)
Mean (SD)

74.74 (6.28)

75.13 (6.48)

75.40 (6.80)

74 (70-79)

74(70-80)

74 (70-80)

Median
(IQR)
66-69

35,472

23.96%

49,710

23.39%

69,073

23.91%

70-74

44,063

29.77%

59,111

27.81%

76,954

26.64%

75-79

35,821

24.20%

50,384

23.71%

63,877

22.11%

80-84

20,465

13.83%

33,387

15.71%

45,993

15.92%

85-89

9105

6.15%

14,839

6.98%

24,064

8.33%

90+

3095

2.09%

5107

2.40%

8905

3.08%

Sex - Female

76,456

51.65%

107,187

50.43%

140,884

48.77%

465

0.31%

809

0.38%

1188

0.41%

1 (lowest)

35,308

23.85%

49,607

23.34%

62,975

21.80%

2

34,709

23.45%

47,862

22.52%

63,610

22.02%

3

29,639

20.02%

41,770

19.65%

57,919

20.05%

4

25,418

17.17%

38,819

18.26%

55,395

19.18%

5 (highest)

22,482

15.19%

33,671

15.84%

47,779

16.54%

72

0.05%

72

0.03%

122

0.04%

No

125,609

84.86%

183,482

86.33%

250,090

86.58%

Yes

22,340

15.09%

28,984

13.64%

38,654

13.38%

Income quintile
Missing

Rural
Missing
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April 1, 2002

April 1, 2007

April 1, 2012

N= 148,021

%

N=212,538

%

N=288,866

%

15,277

10.32%

24,665

11.60%

41,473

14.36%

5650

3.82%

7963

3.75%

10,577

3.66%

Any cancer

37,955

25.64%

55,425

26.08%

79,749

27.61%

Coronary heart
disease
(excluding
angina)

55,221

37.31%

73,074

34.38%

86,904

30.08%

Congestive heart
failure

30,419

20.55%

36,450

17.15%

43,059

14.91%

Peripheral
vascular disease

6000

4.05%

5666

2.67%

4706

1.63%

14,096

9.52%

23,644

11.12%

35,577

12.32%

Stroke/TIA

8182

5.53%

8478

3.99%

9329

3.23%

Neuropathy

1640

1.11%

2683

1.26%

4085

1.41%

Retinopathy

5172

3.49%

4964

2.34%

4563

1.58%

1.06 (1.26)

---

1.31 (1.26)

---

1.40 (1.19)

---

1 (0-2)

---

1 (0-2)

---

1 (1-2)

---

1.88 (1.9)

---

2.04 (1.73)

---

2.21 (1.56)

---

Comorbiditiesa
Chronic kidney
disease
Chronic liver
disease

Dementia

Investigationsb
Mean (SD)
number
cholesterol tests

Median (IQR)
cholesterol tests
Mean (SD)
HbA1c tests
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April 1, 2002

April 1, 2007

April 1, 2012

N= 148,021

%

N=212,538

%

N=288,866

%

Median (IQR)
HbA1c tests

2 (0-3)

---

2 (1-3)

---

2 (1-3)

---

Mean (SD)
creatinine tests

1.93 (2.32)

---

2.23 (2.33)

---

2.41 (2.25)

---

Median (IQR)
creatinine tests

1 (0-3)

---

2 (1-3)

---

2 (1-3)

---

2.68 (3.25)

---

2.34 (2.46)

---

2.18 (1.95)

---

Median (IQR)
glucose tests

2 (1-4)

---

2 (1-3)

---

2 (1-3)

---

At least 1 eye
exam

61,157

41.32%

81,240

38.22%

97,025

33.59%

At least 1 HbA1c
outpatient lab
value

---

---

53,239

25.05%

75,311

26.07%

Mean (SD)
HbA1c (%)

---

---

7.0% (1.2%)

---

7.2% (1.2%)

---

Mean (SD)
glucose tests

Laboratory Datac

Mean (SD)
HbA1c
(mmol/mol)
Median (IQR)
HbA1c

---

---

53 (13.1)

55 (13.1)

6.8% (6.2%7.5%)

7.0% (6.5%7.7%)

---

---

Mean (SD)
HbA1c
(mmol/mol)
51 (44-58)
53 (48-61)
Abbreviations: TIA transient ischemic attack, SD standard deviation, IQR interquartile range,
HbA1c hemoglobin A1c
a
Comorbidities were examined in the 5 years prior.
b
Investigations were examined in the 1 year prior.
c
Lab values were available in the 1 year prior.
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Figure 1. The number of patients with treated diabetes has nearly doubled over the last

decade (2002-2013)
350000

300000

250000

200000

150000

100000

50000

0

Study Quarter

68

69

Figure 2. Antihyperglycemic medication prescriptions 2002
2002-2013

*Drugs prescribed to less than 5% not illustrated (acarbose, acetohexamide, chlorpropamide,
chlorpr
glimepiride, nateglinide, repaglinide, tolbutamide)
Abbreviations: TZD thiazolidinediones
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Figure 3. Hospital encounters for hypoglycemia in treated patients 2002-2013
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Chapter 4

4

Discussion

4.1 Main findings
In the current work we investigated antihyperglycemic medication prescribing and safety in older
adults with diabetes.
We first note that even within the same drug class (sulphonylureas), the hypoglycemia risk of
antihyperglycemic medications differ significantly in routine care. In 2 matched retrospective
cohort studies of older adults newly prescribed glyburide or modified-release gliclazide as
monotherapy or in the presence of metformin, we found that the hypoglycemia risk of glyburide
was over 500% greater than modified-release gliclazide.
Given the increasing availability of antihyperglycemic medications with different safety profiles,
we then carried out an ecological study to examine patterns in antihyperglycemic medication
prescriptions in older adults from 2002 until 2013. Here we note that there has been increasing
uptake of safer medications (including gliclazide) in our region. In this setting, there has been a
decline in the overall percentage of treated patients with an encounter for hypoglycemia.
Although the decline in hypoglycemia observed in recent years may relate to the use of
medications with a lower hypoglycemia risk, additional factors may have also contributed
including changing quality of care, the accuracy of administrative codes, or the characteristics of
patients with the diabetes (ie. their duration of disease, comorbidities etc.).

4.2

General strengths and limitations

There are several strengths to our current work. First, as our studies were observational in design,
we were able to examine a population of older adults with comorbidities who are frequently
excluded from randomized controlled trials. This makes our work generalizable to a larger
population.1,2 Where clinical trials are often limited in their sample size, we were also able to
efficiently study a large sample of these individuals (up to 289,312 in the last quarter of our
antihyperglycemic medication trends investigation).1
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Second we were able to draw upon the rich data contained within Ontario’s health administrative
databases. Ontario’s health administrative databases are a unique combination of the province’s
large population and Canada’s universal health care coverage. The data is recognized for its
comprehensiveness (includes all Ontario residents, vital statistics, physician claims,
hospitalizations and medical procedures), retention (loss to follow-up from emigration is
<0.5%/year), and accuracy (validity of key elements such outpatient drug claims prescribed to
older people).
There are some weaknesses of our work that warrant attention. First, for our glyburide vs
gliclazide drug study, prospective data collection with independent outcome adjudication would
have been a preferred methodology to a retrospective database study. Our trends study was
additionally a general descriptive study and we collected data on groups and not for each
individual within the population. We thus could not determine whether the individuals in whom
hypoglycemia developed were on the agents associated with a higher hypoglycemia risk. As a
result, we could not establish a causal association between drug use and hypoglycemia.3
Second, the potential biases in our studies warrant attention. In our glyburide vs gliclazide study,
our non-random exposure allocation may have led to “indication bias”, a bias frequently
encountered in pharmacoepidemiologic studies. We did however did try to minimize this bias by
using propensity score matching to help ensure that the distribution of measured baseline
characteristics were similar between treated and untreated patients. 2,4
Third, as in all observation studies, residual confounding is an additional consideration. This
occurs where adjustment does not completely remove the confounding effect due to a given
variable or a set of variables.5 In our glyburide vs gliclazide study we had no information on
unmeasured factors such as nutrition, glucose monitoring, patient education, health literacy,
attitudes, and social support which may have influenced the association between sulphonylurea
type and outcome. However, using a matching technique we did obtain good balance on a large
number of measured baseline characteristics between the two groups. As well, the magnitude of
the relative risk of hypoglycemia in these studies were large making it unlikely the association
can be entirely explained by confounding factors.
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Fourth, although we used rich administrative databases to obtain our data, the variables captured
within these databases may not be complete. For example, we were unable to assess medical
conditions that did not result in hospital presentation or physician billing including hypoglycemia
encounters that were self-treated in the home or by emergency medical service personnel. We
were also unable to identify comorbidities, outcomes, and procedures that are not associated with
a specific ICD or billing codes, and were only able to examine procedures covered by the
universal health care system.1 The possibility of information bias thus arises, although we
anticipate that this bias led to non-differential misclassification (ie. that not related to exposure
status but due to a problem inherent in the data sources).2
Fifth, although we could accurately ascertain medications dispensed, we had no information on
medication use. We further could not assess over the counter medications or medications covered
by private drug-funding schemes.
Finally, we assessed the outcome of a hospital encounter with hypoglycemia with administrative
codes which have limited sensitivity and accuracy compared to laboratory plasma glucose
measurements (although the latter is not the best reference standard as treatment with glucose has
frequently been initiated in many hypoglycemic episodes by the time plasma glucose is
measured).

4.3

Conclusions

Antihyperglycemic medications are central to the management of patients with diabetes. These
medications however have very different side effects including risks for hypoglycemia.
In Ontario, there has been an uptake of newer and safer medications in older adults including
gliclazide. In this setting, over the past decade there has been a decrease in the percentage of
treated patients with a hospital encounter with hypoglycemia. The extent to which this finding
relates to the use of safer prescription medications or to other factors remains to be determined.
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4.4

Future research

A closer examination of drug prescribing and safety in older adults with medical comorbidities is
needed. This is especially important for those with chronic kidney disease (CKD).
CKD is a common comorbidity in people with diabetes.6 Patients with CKD are often on
multiple medications, have concomitant comorbidities, and have differences in drug metabolism
and clearance. In this population, hypoglycemia is also a major concern due to diminished renal
gluconeogenesis, and impaired clearance of antihyperglycemic medications.6,7
Given their vulnerabilities, patients with CKD and diabetes need to be treated cautiously.8
Unfortunately, there have been few clinical studies that have been published to assess or guide
the management of this patient population. Our future research efforts then will focus on
antihyperglycemic medication prescribing, safety and efficacy in patients with impaired renal
function.

4.5
1.
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Appendix A
Definitions of Key Terminology
Angiotensin converting enzyme inhibitor – a medication that helps to relax blood vessels and
decrease blood pressure.
Angiotensin receptor blockers – a medication that helps to relax blood vessels and decrease
blood pressure.
Antihyperglycemic medications – medications that work to lower blood sugar.
Antiplatelet therapy – medications that help to prevent the formation of blood clots.
Autoimmune disease – disease where one’s immune system inappropriately attacks healthy body
cells/tissues.
Autonomic nerves – nerves that help to control involuntary actions such as digestion, heart rate,
and vessel tone.
Bariatric surgery – weight-reduction surgery.
Chronic kidney disease – chronic loss of kidney function.
Cognitive function – involves one’s memory, language, thinking and judgment.
Combination therapy – the use of 2 or more medications.
Counter-regulatory response – body’s stress response to hypoglycemia, mediated by the release
of hormones and neurotransmitters.
Debridement – the removal of dead or damaged body tissue.
Diabetic ketoacidosis – diabetes emergency that leads to hyperglycemia and the accumulation of
ketones (breakdown product of fat).
Diagnostic – concerned with the identification of an illness/process.
76

77

Dopamine antagonists – drugs which block the body’s dopamine receptors.
Drug formulary – a collection of drugs funded by the province’s drug benefit program.
Exceptional access program – program which facilitates the funding of medications that are not
covered by the province’s drug benefit program.
Exudate – fluid which escapes from the body’s blood vessels.
Gangrene – condition which occurs when body tissue dies.
Gastroparesis – impaired motility of the stomach.
Glycemic control – control of blood sugar.
Glycosylated hemoglobin (HbA1c)– laboratory measure which reflects blood sugar control over
the previous 8-12 weeks.
Health literacy - the ability to access, comprehend, evaluate and communicate health
information.
Hyperglycemia – high blood sugar.
Hyperglycemic hyperosmolar state – diabetes emergency that leads to extremely high blood
sugar and dehydration, without the accumulation of ketones.
Hypoglycemia – low blood sugar.
Hypoglycemia unawareness – occurs when one has greater tolerance to low blood sugar and does
not feel its associated symptoms.
Insulin – hormone responsible for the storage and utilization of glucose in the body.
Insulin deficiency – lack of insulin.
Insulin resistance – poor utilization of insulin.
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Intensive glycemic control – blood sugar control that targets a glycosylated hemoglobin less than
7%.
Ischemia – lack of oxygen to a tissue.
Lipid disorder – abnormality of cholesterol and triglycerides.
Lipid lowering medications – medications that work to lower cholesterol and triglycerides.
Macrovascular disease – disease of the large blood vessels of the body (ie. heart, brain,
periphery).
Macular edema – occurs when fluid leaks from the blood vessels in the eyes.
Metabolic condition – disease caused by a disruption in the chemical reactions in the body.
Microvascular disease – disease of the small blood vessels of the body (ie. eyes, kidney, nerves).
Microaneurysms – small aneurysm or swelling of the blood vessels in the eye.
Monotherapy – the use of 1 medication.
Motor nerves – nerves that act on the muscles.
Nephropathy – damage to the kidneys.
Neuropathy – damage to the nerves of the body.
Number needed to harm - estimate of how many people need to receive a treatment before one
more person would experience a harmful outcome.
Odds ratio – the ratio of odds of the development of disease in exposed people to the odds of the
development of disease in unexposed people.
Oral glucose tolerance test – a test which measures how well the body breaks down sugar.
Pancreatic beta cell – cell of the pancreas that is responsible for the production of insulin.
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Photocoagulation- a surgical procedure which involves the clotting of eye tissue with a laser.
Procedural – refers to a task or operation.
Relative risk – describes disease risk in exposed people relative to the disease risk in unexposed
people.
Retinopathy – disease of the eyes.
Retinal detachment – occurs when the retina (eye tissue) separates from the back of the eye.
Risk difference – difference in observed risks between groups.
Sensory nerves – nerves that transmit sensation information.
Structural complications – refer to the microvascular and macrovascular complications of
diabetes.
Urinary incontinence- the loss of bladder control.
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STROBE guidelines
Table 2. Coding definitions for demographic and co-morbid conditions
Table 3. Coding definitions for hospital presentation with hypoglycemia and all-cause
mortality
Table 4. Characteristics of patients with and without baseline laboratory values (serum creatinine
or HbA1c) in the monotherapy and metformin combination study
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Figure 1. Flow diagram representing monotherapy study inclusions and exclusions
Figure 2. Flow diagram representing metformin combination study inclusions and exclusions
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Table 1: Checklist of recommendations for reporting of observational studies using the
STROBE guidelines

Title and abstract

Item
No

Recommendation

1

(a) Indicate the study’s design with a commonly used
term in the title or the abstract
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found

Reported
Abstract
Abstract

Introduction
Background/rationale

2

Objectives

3

Methods
Study design

4

Setting

5

Participants

6

Explain the scientific background and rationale for the
investigation being reported
State specific objectives, including any pre-specified
hypotheses

Variables

7

Data sources/
measurement

8

Bias

9

Present key elements of study design early in the paper
Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure, follow-up,
and data collection
(a) Give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods
of follow-up
(b) For matched studies, give matching criteria and
number of exposed and unexposed
Clearly define all outcomes, exposures, predictors,
potential confounders, and effect modifiers. Give
diagnostic criteria, if applicable
For each variable of interest, give sources of data and
details of methods of assessment (measurement).
Describe comparability of assessment methods if there
is more than one group
Describe any efforts to address potential sources of bias

Study size

10

Explain how the study size was arrived at

Quantitative
variables

Statistical methods

11

12

Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why
(a) Describe all statistical methods, including those
used to control for confounding
(b) Describe any methods used to examine subgroups
and interactions
(c) Explain how missing data were addressed

Introduction
Introduction

Methods
Methods

Methods
Methods
Methods

Appendix B Table 2
and 3
Discussion
Methods, based on
availability of the
data
Methods
Methods
Methods
Not Applicable
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(d) If applicable, explain how loss to follow-up was
addressed
(e) Describe any sensitivity analyses

Not Applicable
Methods

Results
(a) Report numbers of individuals at each stage of
study—e.g. numbers potentially eligible, examined for
eligibility, confirmed eligible, included in the study,
completing follow-up, and analyzed
Participants

13

(b) Give reasons for non-participation at each stage

Results, Appendix B
Figure 1 and 2
Appendix B Figure 1
and 2
Appendix B Figure 1
and 2

(c) Consider use of a flow diagram

Descriptive data

Outcome data

Main results

Other analyses

14

15

16

17

(a) Give characteristics of study participants (e.g.
demographic, clinical, social) and information on
exposures and potential confounders
(b) Indicate number of participants with missing data
for each variable of interest
(c) Summarize follow-up time (e.g. average and total
amount)
Report numbers of outcome events or summary
measures over time
(a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision (e.g.
95% confidence interval). Make clear which
confounders were adjusted for and why they were
included
(b) Report category boundaries when continuous
variables were categorized
(c) If relevant, consider translating estimates of relative
risk into absolute risk for a meaningful time period
Report other analyses done—e.g. analyses of subgroups
and interactions, and sensitivity analyses

Results, Table 3 and
4
Results
Results
Results

Results, Table 5 and
6

Table 3 and 4
Results, Table 5 and
6
Results

Discussion
Key results

18

Limitations

19

Interpretation

20

Summarize key results with reference to study
objectives
Discuss limitations of the study, taking into account
sources of potential bias or imprecision. Discuss both
direction and magnitude of any potential bias
Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other relevant
evidence

Discussion
Discussion

Discussion
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Generalizability

21

Discuss the generalizability (external validity) of the
study results

Discussion

22

Give the source of funding and the role of the funders
for the present study and, if applicable, for the original
study on which the present article is based

Cover page,
Disclosures

Other information
Funding
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Table 2: Coding definitions for demographic and comorbid conditions
Characteristics/Condition

Database

Age

RPDB

Sex

RPDB

Socioeconomic Status

Statistics Canada

Rural Location

Statistics Canada

Long Term Care Utilization

ODB

Charlson Comorbidity Index

CIHI-DAD

Health Care Visits
Prescribing Physician

OHIP
IPDB
IPDB

Alcoholism

CIHI-DAD

Codes

ICD 9: 303, 3050
ICD 10: E24, E512, F10, G312, G621, G721,
I426, K292, K70, K860, T510, X45, X65, Y15,
Y573, Z502, Z714, Z721

Chronic Kidney Disease

CIHI-DAD

ICD 9: 4030, 4031, 4039, 4040, 4041, 4049, 585,
586, 5888, 5889, 25040
ICD 10: E102, E112, E132, E142, I12, I13, N08,
N18, N19

Chronic Liver Disease

OHIP
CIHI-DAD

OHIP DX: 403, 585
ICD 9: 4561, 4562, 070, 5722, 5723, 5724, 5728,
573, 7824, V026, 2750, 2751, 7891, 7895, 571
ICD 10: B16, B17, B18, B19, I85, R17, R18,
R160, R162, B942, Z225, E831, E830, K70,
K713, K714, K715, K717, K721, K729, K73,
K74, K753, K754, K758, K759, K76, K77
OHIP DX: 571, 573, 070

Carotid Ultrasound

OHIP
CIHI-DAD

OHIP FEE: Z551, Z554
CCP: 0281
CCI: 3JE30

OHIP

OHIP FEE: J201, J501, J189, J489, J190, J191,
J490, J491, J492
84

85

Coronary Angiogram

CIHI-DAD

CCP: 4892, 4893, 4894, 4895, 4896, 4897, 4898,
4996, 4997
CCI: 3IP10

Coronary Revascularization

OHIP

OHIP FEE: G297, Z442

CIHI-DAD

CCP: 481, 482, 483, 480
CCI: 1IJ50, 1IJ26, IIJ27, 1IJ57, 1IJ76

OHIP
Echocardiography

CIHI-DAD

OHIP FEE: R741, R742, R743, E651, E652, E654,
E646, G298, Z434, G262
CCP: 0282
CCI: 3IP30

OHIP

Holter Monitoring

CIHI-DAD
OHIP

Stress Test

CIHI-DAD

OHIP FEE: G560, G561, G562, G566, G567,
G568, G570, G571, G572, G574, G575, G576,
G577, G578, G579, G580, G581
CCI: 2HZ24JAKH
OHIP FEE: G650, G651, G652, G653, G654,
G655, G656, G657, G658, GG59, G660, G661,
G682, G683, G684, G685, G686, G687, G688,
G689, G690, G692, G693
CCP: 0341, 0342, 0343, 0344
CCI: 2HZ08, 3IP70

OHIP

Glycosylated Hemoglobin Test

OHIP

OHIP FEE: G315, G174, G111, G112, G319,
J604, J606, J607, J608, J611, J612, J613, J667,
J807, J808, J809, J804, J811, J812, J813, J867,
J609, J666, J866
OHIP FEE: L093

Diabetic Retinopathy

CIHI-DAD

ICD 9: 3602, 2505

Diabetes Management

OHIP

ICD 10: E1030, E1031, E1032, E1033, E1130,
E1131, E1132, E1133, E1330, E1331, E1332,
E1333, E1430, E1431, E1432, E1433, H360
OHIP FEE: K030

Diabetes Incentive

OHIP

OHIP FEE: Q040
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Coronary Artery Bypass Graft

CIHI-DAD

CCI: 1IJ50, 1IJ76
CCP: 4802, 4803, 4809, 4811, 4812, 4813, 4814,
4815, 4816, 4817, 4819

Peripheral Vascular Disease

CIHI-DAD

OHIP FEE: Z434, R742, R743
ICD 9: 4402, 4408, 4409, 5571, 4439, 444
ICD 10: I700, I702, I708, I709, I731, I738, I739,
K551
CCP: 5125, 5129, 5014, 5016, 5018, 5028, 5038
CCI: 1KA76, 1KA50, 1KE76, 1KG26, 1KG50,
1KG57, 1KG76MI, 1KG87

OHIP

Heart Failure

CIHI-DAD

OHIP FEE: R787, R780, R797, R804, R809,
R875, R815, R936, R783, R784, R785, E626,
R814, R786, R937, R860, R861, R855, R856,
R933, R934, R791, E672, R794, R813, R867,
E649
ICD 9: 425, 5184, 514, 428
ICD 10: I500, I501, I509, I255, J81
CCP: 4961, 4962, 4963, 4964
CCI: 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR,
1HZ53SYFR

Sepsis

OHIP

OHIP FEE: R701, R702, Z429

CIHI-DAD

OHIP DX: 428
ICD 9: 0031, 0380, 0381, 0382, 0384, 0388, 0389,
0545
ICD 10: A40, A41, R572

Pituitary Disease

OHIP
CIHI-DAD

OHIP DX: 038
ICD 9: 253, 2550
ICD10: E22, E23, E24

Adrenal Disease

OHIP
CIHI-DAD

OHIP DX: 253
ICD9: 2552, 2553, 2554, 2555, 2556, 2558, 2559,
7591, 0363
86

87

ICD10: E25, E27, E351, Q891

Thyroid Disease

OHIP
CIHI-DAD

OHIP DX: 255
ICD 9: 243, 244, 245, 246
ICD 10: E01, E03, E04, E05, E06, E07

Pancreatitis

OHIP
CIHI-DAD

OHIP DX: 242, 243, 244, 245
ICD 9: 5770, 5771, 0723

Pancreatectomy

CIHI-DAD

ICD 10: K85, B252, B263, K860, K861
CCI: 1OJ87, 1OJ89, 1OK87, 1OK89, 1OK91

CIHI-DAD

CCP: 6440, 6441,6442, 6443, 6449, 6450, 6460
ICD 9: 1570, 1571, 1572, 1573, 1574, 1578, 1579

Pancreatic Cancer

ICD10: C250, C251, C252, C253, C254, C257,
C258, C259
OHIP DX: 157
Abbreviations: CCI, Canadian Classification of Health Interventions; CIHI-DAD, Canadian Institute
for Health Information Discharge Abstract Database; CCP, Canadian Classification of Diagnostic,
Therapeutic and Surgical Procedures; ICD9, International Classification of Diseases, 9th revision;
ICD10, International Classification of Diseases, 10th revision; IPDB, Institute for Clinical Evaluative
Sciences Physician Database; OHIP DX, Ontario Health Insurance Plan Diagnostic Code; OHIP FEE,
Ontario Health Insurance Plan Fee Code; RPDB, Registered Persons Database of Ontario.
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Table 3: Coding definitions for hospital presentation with hypoglycemia and all-cause
mortality

Condition
Hypoglycemia
Mortality b

a

Database

Codes

CIHI-DAD
NACRS

ICD10: E15, E160, E161,
E162, E1063, E1163,
E1363, E1463

RPDB

Vital status field

a

We established a validation study of hypoglycemia codes in an emergency room or inpatient
setting using linked laboratory plasma glucose values in Ontario. In a cohort of 69,382 patients
in the emergency room setting, hypoglycemia codes (ICD10: E15, E160, E161, E162, E1063,
E1163, E1363, E1463) had a sensitivity of 21.8%, specificity of 99.5%, PPV 28.7%, NPV 99.2%
for glucose values <3.9 mmol/L. For glucose values <3.0 mmol/L, hypoglycemia codes had a
sensitivity of 33.3%, specificity 99.4%, PPV 18.1%, NPV 99.7%. In a cohort of 47,377 patients
admitted to hospital, hypoglycemia codes had a sensitivity of 7.3%, specificity 99.5%, PPV
46.0%, NPV 94.9% for glucose values <3.9 mmol/L at the time of hospital presentation. For
glucose values <3.0 mmol/L at the time of hospital presentation, hypoglycemia codes had a
sensitivity 11.5%, specificity 99.4%, PPV 30.2%, and NPV 98.0%. We recognize laboratory
plasma glucose values are not an ideal reference standard since in some instances hypoglycemia
may have been treated by paramedics or the patient themselves prior to presenting to a hospital
setting. Furthermore, hypoglycemia may have been detected and treated based upon point of
care capillary testing which may not have been documented in the laboratory setting.
b
Mortality has a sensitivity of 94% and a positive predictive value of 100%. See Jha P, Deboer
D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial
participants and nonparticipants: a population based comparison . J Am Coll Cardiol 1996;
27:1335-42
Abbreviations: CIHI-DAD, Canadian Institute for Health Information Discharge Abstract
Database; ICD10, International Classification of Diseases, 9th revision; NACRS, National
Ambulatory Care Reporting System Database; RPDB, Registered Persons Database of Ontario.
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Table 4: Characteristics of patients with and without baseline laboratory values (serum
creatinine or HbA1c) in the monotherapy and metformin combination study

Monotherapy Study

Total
Age at Index Date
Mean (SD)
Median (IQR)
66-70 years
71-75 years
76-80 years
81-85 years
86-90 years
>90

Female
Income based
socioeconomic status b
Quintile 1
(lowest)

No lab
values
6744

Lab values
2004

75.79
(7.10)

75.21
(6.82)

75 (70-81)

74 (69-80)

1978
(29.33)
1600
(23.72)
1371
(20.33)
1072
(15.90)

Standardized
Difference

615 (30.69)

3%

510 (25.45)

4%

427 (21.31)

2%

271 (13.52)

7%

544 (8.07)

138 (6.89)

4%

179 (2.65)

43 (2.15)

3%

3331
(49.39)

945 (47.16)

4%

Metformin Combination Study
Standardized
No lab
Lab
Differencea
values
values
11,663
4413
73.40
(6.09)
72 (6877)
4669
(40.03)
3161
(27.10)
2142
(18.37)
1198
(10.27)
387
(3.32)
106
(0.91)
5397
(46.27)

73.16
(5.84)
72 (6877)
1804
(40.88)
1212
(27.46)
829
(18.79)
406
(9.20)
141
(3.20)
21
(0.48)
2017
(45.71)

2%
1%
1%
4%
1%
5%
1%

2569
939
1444
0%
2%
431 (21.51)
(22.03) (21.28)
(21.41)
2574
1012
1479
6%
2%
492 (24.55)
(22.07) (22.93)
Quintile 2
(21.93)
Quintile 3
1352
2379
919
391 (19.51)
1%
1%
(middle)
(20.05)
(20.40) (20.82)
2219
821
1315
2%
1%
378 (18.86)
(19.03) (18.60)
Quintile 4
(19.50)
Quintile 5
1154
1922
722
312 (15.57)
4%
0%
(highest)
(17.11)
(16.48) (16.36)
851
1550
478
175 (8.73)
13%
8%
Rural Location
(12.62)
(13.29) (10.83)
Data presented as number (percent) except where indicated.
Abbreviations: HbA1c glycosylated hemoglobin, IQR interquartile range, SD standard deviation
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a

Standardized differences are less sensitive to sample size than traditional hypothesis tests. They
provide a measure of the difference between groups divided by the pooled standard deviation; a
value greater than 10% is interpreted as a meaningful difference between groups.
b
Income was categorized into fifths of average neighborhood income on the index date.
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Table 5: Events in monotherapy study time to event analysis
Censoring events

Glyburide

Gliclazide

n=4374

n=4374

3115.5 person years of follow- 4355.2 person years of followup
up
Median (IQR) days of followup, 79.5 (30 to 230)

Median (IQR) days of followup, 150 (48 to 520)

Number of events

94 (2.2%)

20 (0.5%)

Event rate per 1000 person
years

30.2

4.6

Death

7 (0.2%)

12 (0.3%)

Study sulphonylurea
discontinued

3529 (80.7%)

3605 (82.4%)

Prescription for a non-study
oral hypoglycemic agent or
insulin

744 (17.0%)

737 (16.9%)

Hospital encounters with
hypoglycemia

Censoring events
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Table 6: Events in metformin combination study time to event analysis
Censoring events

Glyburide

Gliclazide

n=8038

n=8038

6973.4 person years of follow- 9101.6 person years of followup
up
Median (IQR) days of followup, 90 (30 to 323)

Median (IQR) days of followup, 192.5 (49 to 669)

Number of events

205 (2.6%)

41 (0.5%)

Event rate per 1000 person
years

29.4

4.5

Death

11 (0.1%)

7 (0.1%)

Study sulphonylurea
discontinued

6843 (85.1%)

6948 (86.4%)

Prescription for non-study oral
hypoglycemic agent or insulin

979 (12.2%)

1042 (13.0%)

Hospital encounters with
hypoglycemia

Censoring events
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Figure 1: Flow diagram representing monotherapy study inclusions and exclusions

Patients with an outpatient prescription for oral
hypoglycemic agent between April 2002 and
December 2011
(n = 274,896)

Patients excluded from study (n = 256,092)
Age <66 at the time of oral hypoglycemic agent prescription:
12,756
Evidence of insulin or oral hypoglycemic agent dispensed in 1 year
prior to index date: 227,727
Evidence of medication commonly associated with hypoglycemia in
1 year prior to index date: 681
Evidence of at least 1 hospital encounter with hypoglycemia in 5
years prior to the index date: 543
Evidence of end-stage renal disease in 5 years prior to the index
date: 753
Evidence of hospital discharge in the 2 days prior to or on index
date: 2583
Ineligible study dose: 11,049

Patients included in study before
matching (n = 18,804)
Glyburide users: 13,550
Gliclazide MR users: 5254

Patients included in study after matching
(n = 8748)
Glyburide users: 4374
Gliclazide MR users: 4374
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Figure 2: Flow diagram representing metformin combination study inclusions and
exclusions
Patients with an outpatient prescription for oral
hypoglycemic agent between April 2002 and
December 2011
(n = 274,969)

Patients excluded from study (n = 248,371)
No evidence of one or more metformin prescription dispensed
on the index date or in the 180 days prior to the index date:
78,694
Age <66 at the time of oral hypoglycemic agent prescription:
12,445
Evidence of insulin or other oral hypoglycemic agent dispensed
in 1 year prior to index date (besides metformin): 145,139
Evidence of medication commonly associated with
hypoglycemia in 1 year prior to index date: 706
Evidence of at least 1 hospital encounter with hypoglycemia in 5
years prior to the index date: 522
Evidence of end-stage renal disease in 5 years prior to the
prescription date: 217
Evidence of hospital discharge in the 2 days prior to or the index
date: 2940
Ineligible study dose: 7708

Patients included in study before
matching (n = 26,598)
Glyburide users: 16,631
Gliclazide MR users: 9967

Patients included in study after matching
(n = 16,076)
Glyburide users: 8038
Gliclazide MR users: 8038
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Appendix C
Dataset Creation Plan for “The Hypoglycemic Risk of Glyburide
Compared with Modified Release Gliclazide”

Number of Study

Contacts

PIA Approved?

2014 0906 038 000
Jamie Fleet
Amit Garg
Stephanie Dixon
Kristin Clemens
Yes
Version 0 – May 21st 2013 (JF)
Version 1 – July 8th 2013 (JF after comments from AG and EM)

Update History.doc

DCP update history

Version 2 – July 22nd 2013 (JF after meeting with KC, AG, EM)
Version 3 – Aug 15, 2013 (KC after meeting with AG, EM)
Version 4 – December 20, 2013 (KC)
Version 5 – December 31, 2013 (KC after comments from AG)
Version 6 – November 26th, 2014 (based on the recommendations of CJD)

Oral hypoglycemic agents are used to help control diabetes mellitus. We
will explore the risk of a hospital encounter with hypoglycemia in new,
Short Description of Research Question
older adult users of these medications – specifically in users of glyburide
vs modified-release gliclazide.
RPDB
ODB
Population
Age 65+

List of Datasets Used

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
OHIP
Claim Type
Nonlab
NACRS
Source
95
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Emergency Department visits
Include planned visits

No
Include suspected/questionable diagnoses?
No
Gamma-Dynacare
Type of test
Serum creatinine ‘/home/sdixon/data/GD/fullSCr’
Hemoglobin A1C – test number 093D
Glucose serum fasting – test number 111G
Glucose serum random – test number 111H
Cerner
File name: /ices/CDP/cerner/cerner_apr99_dec10.sas7bdat
Hospital Stay
Inpatient (Disposition = “Inpatient”)
Outpatient (Disposition = “Outpatient”)
Emergency Room (Disposition = “Emergency Room”)
Type of test
Serum creatinine in µmol/L (Test_Done = “A”)
Serum glucose in mmol/L (Test_Done = “B”)

Defining the Cohort
Index Event

Prescription for new sulphonylurea medication

Inclusion –
Cohorts A

Patients with an outpatient prescription for a study oral hypoglycemic agent (OHA) from ODB
from April 1st 2002 to Dec 31st 2011 in one of the following DCLASSes:, S_GLY, S_GLC,
This date will be the OHA prescription date

Exclusions –
Cohorts A

1.

2.
3.

4.
5.

Data cleaning
a. Invalid IKN
b. Missing age/sex
c. Non-Ontario resident (CIHI variable prdcddablk does not begin with “35”)
d. Death on or before OHA prescription date
Age <66 on OHA prescription date
Evidence of any previous OHA in the 1 year prior (DCLASS: S_MET, S_GLY,
S_GLC, S_GLM, S_REP, S_ROS, S_PIO, S_SIT, S_SAX, S_LIN, S_ACB, S_INS,
S_MES) or more than 1 DCLASS type on the prescription date
Evidence of the following drugs in the 1 year prior to prescription date that have been
linked to hypoglycemia (DCLASS = EX)
Evidence of hypoglycemia in ER or hospital in 5 years prior to prescription date

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
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Diagnosis Type (dxtype)
All (alldx)
NACRS
Source
Emergency Department visits
Include planned visits

No
Include suspected/questionable diagnoses?
No

hypoglycemia.txt

6.

Evidence of any dialysis in the 1 year prior, or renal transplant in the 5 years prior (one
or more of the codes below)

dialysis exclusion renal transplant.txt
with pre 2002 codes.txt

7.
8.
Dose

Gliclazide Modified
Release

Glyburide

1

30mg

5mg

2

60mg

10mg

3

90g

15mg

4

120mg

20mg

9.
Inclusion –
Cohorts B
Exclusions –
Cohorts B

Evidence of hospital discharge up to 2 days prior to or on OHA prescription date
Restrict to study doses as follows:

Note: This also requires exclusion of gliclazide non-modified release: DCLASS = NS
If more than one eligible prescription is available, restrict to first

Patients with an outpatient prescription for a study oral hypoglycemic agent (OHA) from ODB
from April 1st 2002 to Dec 31st 2011 in one of the following DCLASSes: S_GLY, S_GLC,
This date will be the OHA prescription date
1.

2.

Look back 180 days from OHA prescription date for at least 1 prescription for
metformin (DCLASS = S_MET). This includes evidence of S_MET first prescribed on
the index date. Exclude if does not meet this criteria (i.e. exclude if no evidence of
prior metformin use, either in the preceding days or co-prescribed with the oral
hypoglycemic of interest on the index date)
•

See drug list in Appendix A

•

Note: The day supply of the most recent metformin prescription [i.e. the most
recent metformin prescription prior to OHA prescription date] must cross the OHA
prescription date (if co-prescribed on the same day then not an issue).

Data cleaning
a. Invalid IKN
b. Missing age/sex
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c. Non-Ontario resident (CIHI variable prdcddablk does not begin with “35”)
d. Death on or before OHA prescription date
3. Age <66 on OHA prescription date
4. Evidence of any previous OHA other than metformin in the 1 year prior (DCLASS:
S_GLY, S_GLC, S_GLM, S_REP, S_ROS, S_PIO, S_SIT, S_SAX, S_LIN, S_ACB,
S_INS) or more than 1 DCLASS (except S_MET) type on the prescription date
5. Evidence of the following drugs that have been linked to hypoglycemia (DCLASS =
EX)
6. Evidence of hypoglycemia in ER or hospital in 5 years prior to prescription date (see
cohort A for codes)
7. Evidence of any dialysis in the 1 year prior, or renal transplant in the 5 years prior (one
or more of the codes in Cohort A and B exclusions)
8. Evidence of hospital discharge up to 2 days prior to or on OHA prescription date
10. Restrict to study doses as follows:
Dose

Gliclazide Modified
Release

Glyburide

1

30mg

5mg

2

60mg

10mg

3

90g

15mg

4

120mg

20mg

9.

Note: This also requires exclusion of gliclazide non-modified release: DCLASS = NS
If more than one eligible prescription is available, restrict to first

Time Frame Definitions

Observation Window

Accrual Start/End April 1st 2002 to December 31st 2011
Dates
Max Follow-up
Date
When does the
observation
window
terminate?
Lookback
Window

Exposure

March 31st 2012
1.
2.
3.

90 days after index
Death
Max follow-up (March 31, 2012)
120 days for baseline medications
5 years for comorbidities
1 year for OHA’s
1 year for labs
New sulphonylurea prescription – glyburide vs modified-release gliclazide
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Variable Definitions
Outcome Definitions

NACRS
Source
Emergency Department visits
Include planned visits

No
Include suspected/questionable diagnoses?
No
CIHI-DAD
Source
Inpatient
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)

RPDB
90 day outcomes
below)
1. Emergency room visit or Hospitalization with hypoglycemia

hypoglycemia.txt

2.

All-cause mortality

Propensity Score Definition See Appendix A (Drug list) and D for baseline codes, drug list and additional details
•

The propensity score is defined as the probability of exposure (E)
conditional on the covariates (See variables below): Pr (E=1IX1, X2,
X3, …, Xn)

•

We will obtain a propensity score per patient (in both the gliclazide
and glyburide groups) by fitting a logistic model (proc logistic) that
estimates the probability of an OHA prescription given the
covariates below and extracting the predicted probabilities

•

Consider the following variables in the derivation of the propensity
score using multivariable logistic regression model:
Demographics
Age at index year (per year)
Sex (men or women; referent = women)
Location of residence (urban or rural; referent = urban; include
patients with ‘missing’ in the referent group for the purpose of
developing propensity score)

99
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Socioeconomic status (neighbourhood income quintile) (quintiles
1,2,3,4 or t; include patients with ‘missing’ in quintile 3 for the
purpose of developing the propensity score)
Residential status (community-dwelling or long-term care;
referent=community dwelling)
Charlson score (0, 1, 2, or ≥3; include patients with ‘missing’ as
score of 0 for the purpose of developing the propensity score)
Comorbidities
Alcoholism (yes/no; referent=no)
Chronic kidney disease (yes/no; referent=no)
Chronic liver disease (yes/no; referent = no)
Diabetic retinopathy (yes/no; referent=no)
PVD (yes/no; referent=no)
Heart failure (yes/no; referent=no)
Sepsis (yes/no; referent=no)
Pituitary disease (yes/no; referent=no)
Adrenal issues (yes/no; referent=no)
Thyroid disease (yes/no;referent=no)
Pancreatitis (yes/no; referent=no)
Cystic fibrosis (yes/no; referent = no)
Pancreatectomy (yes/no; referent=no)
Pancreatic cancer (yes/no; referent=no)
Diabetic neuropathy (yes/no; referent=no)
Dementia (yes/no; referent = no)
Health Care Utilization
Nephrologist visit (0, 1, 2, ≥3; referent = no)
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Cardiologist visit (0, 1, 2, ≥3; referent = no)
Ophthalmologist visit (0, 1, 2, ≥3; referent = no)
Endocrinologist visit (0, 1, 2, ≥3; referent = no)
Internist visit (0, 1, 2, ≥3; referent = no)
Carotid ultrasound (yes/no; referent=no)
Coronary angiogram (yes/no; referent=no)
Coronary revascularization (yes/no; referent=no)
Echocardiography (yes/no; referent=no)
Holter monitoring (yes/no; referent =no)
Stress test (yes/no; referent = no)

CABG (yes/no; referent=no)
Glycosylated hemoglobin (yes/no; referent=no)
Diabetes management (yes/no; referent = no)
Diabetes incentive (yes/no; referent=no)
Diabetes management by a specialist (yes/no; referent = no)
Diabetes management by a specialist team (yes/no; referent=no)
Prescribed Medication use (120 day look-back)
Acetohexamide (yes/no; referent=no)
ACE inhibitors (yes/no; referent=no)
ARBs (yes/no; referent=no)
Aliskiren (yes/no; referent=no)
Beta blockers (yes/no;referent=no)
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Ezetimibe (yes/no; referent=no)
Fibrates (yes/no; referent = no)
Glucose test strips (yes/no; referent = no)
Loop diuretics (yes/no; referent = no)
Potassium sparing diuretics (yes/no; referent = no)
Statins (yes/no; referent = no)
Thiazide diuretics (yes/no; referent = no)
Gatifloxacin/Levofloxacin (yes/no; referent = no)
Pentamidine (yes/no; referent = no)
Quinine (yes/no; referent = no)
Indomethacin (yes/no; referent = no)
Tacrolimus/sirolimus (yes/no; referent=no)
Clonidine (yes/no; referent = no)
Chloramphenicol (yes/no; referent = no)
H2 Receptor Antagonist (yes/no; referent = no)
Clarithromycin (yes/no; referent = no)
Cyclosporine (yes/no; referent=no)
Fluconazole/voriconazole/miconazole (yes/no;referent =no)
Pegvisimont (yes/no; referent=no)
Probenecid (yes/no; referent=no)
Rifampin (yes/no; referent =no)
Amiodarone (yes/no; referent = no)
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Valproic acid (yes/no; referent=no)
Aprepitant (yes/no; referent=no)
Bosentan (yes/no; referent = no)
Carbamazepine (yes/no; referent = no)
Antidepressants (yes/no; referent = no)
Protease inhibitors (yes/no; referent = no)
Atypical antipsychotics (yes/no; referent = no)
Corticosteroids (yes/no; referent = no)
Sulfonamide (yes/no; referent = no)
MAOI inhibitor (yes/no; referent = no)
Barbiturate (yes/no; referent = no)
Tetracycline (yes/no;referent = no)
Danazol (yes/no; referent = no)
Thyroid replacement (yes/no; referent =no)
Androgen (yes/no; referent = no)
Disopyramine (yes/no; referent = no)
Guanethidine (yes/no; referent = no)
Ifosfamide (yes/no; referent = no)
Phenylbutazone (yes/no; referent = no)
Diazoxide (yes/no; referent = no)
Isoniazid (yes/no; referent = no)
Colesevelam (yes/no; referent = no)
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Reserpine (yes/no; referent = no)
Laboratory Testing (baseline characteristic only - not to be
included in the propensity score):
For Cohorts A and B (both pre and post matching), where available,
provide:
-Number (%) with creatinine in the 1 year prior
-Mean (SD) creatinine
-Median (IQR) creatinine
-Mean (SD) eGFR
-Median (IQR) eGFR
-Number (%) with hemoglobin A1c in the 1 year prior
-Mean (SD) hemoglobin A1c
-Median (IQR) hemoglobin A1c

Hard and Propensity Score
Matching

•

We will use greedy matching with specified caliper width of
(plus/minus) 0.6 x the standard deviation of the logit of the
propensity score

•

The difference in the logit of the propensity score between the
gliclazide and the glyburide groups in the matched set is required to
be less than the pre-specified maximum caliper wide

•

We will match without replacement. Matching gliclazide patients
can no longer serve as a candidate for being matched to another
glyburide patient

Matching Ratio: We will match 1 gliclazide patient with 1 glyburide patient on:
•

The logit of the propensity score

•

Age at the index date (plus/minus 2 years)

•

Sex (men or women; referent=women)

•

CKD status (yes/no; referent = no)

•

Medication dose

•

At least 1 endocrinologist visit

Dose

Gliclazide Modified
Release

Glyburide

1

30mg

5mg

2

60mg

10mg

3

90g

15mg

4

120mg

20mg
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Outline of Analysis Plan
1. Cohort Creation
• Show prescriptions and unique IKNs that are included at each stage
• Table 1A – Cohort A creation
• Table 1B – Cohort B creation
2. Aggregate Event Rate
• Show total number of patients, and broken down by CKD and no-CKD by codes
• Show number and proportion of patients with events in each category
• Table 2A – Cohort A
• Table 2B – Cohort B
3. Prescription Breakdown
• Show number with each prescription type
• Show min, max, median, IQR average daily dose for each prescription
• Table 3A – Cohort A
• Table 3B – Cohort B
• Note: For cohort B show how many prescriptions for metformin in 120 days prior to
OHA prescription date (min # prescriptions, max # prescriptions, median # prescriptions,
25th percentile # of prescriptions, 75th percentile # of prescriptions). See Table 3D, 3E,
3F
4. Continuous Usage
• Show only for patients who have at least one year of prescriptions (those accrued no
later than March 31st 2011; have done this to allow for the possibility of at least one full
year of follow-up data)
• Look forward to end of day supply for last eligible prescription to assess continuous
usage in number of days.
• If index script is the only prescription, look to the end of its day supply.
• Eligible prescriptions are those in the same DCLASS and with a subsequent
prescription a max of 10 days following the end of day supply of the previous prescription
(ie. could be before 10 days for next prescription)
• Person is no longer the continuous user if:
o No more evidence of the DCLASS 10 days after end of prior prescription day supply
o switch to a different DCLASS
o die
o end of follow up (March 31st 2012)
5. Metformin Usage After Index – Cohort A and B
• Show number of patients with ≥1 S_MET prescription within 180 days following the
index date (not including the index date)
6. Baseline characteristics
• Show number and proportion with standardized differences comparing S_GLY and
S_GLC for each characteristic listed in Appendix D
• Look back 5 years for comorbidities, 1 year for lab values (where available), and 120
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days for medications unless otherwise specified
• Table 6a is for COHORT A prior to matching and includes laboratory values
• Table 6c is for COHORT A post-matching and includes laboratory values
• Table 6b is for COHORT B prior to matching and includes laboratory values
• Table 6d is for COHORT B post-matching and includes laboratory values
7. Primary Analysis
• Conditional logistic regression model looking at S_GLY vs. S_GLC with a 90 day
follow up
• Table 7 are for COHORT A – total cohort (all outcomes)
• Table 8 are for COHORT B – metformin (all outcomes)
9. Secondary analyses
Costs of SU to ODB
·Time to event analysis (censoring on death, receipt of non-study OHA, discontinuation of
study OHA)
·Physician associated factors with prescription for glyburide from 2008-2011 (time since
grad, origin of training, practice location
·Characteristics of hypoglycemia episodes (time of day, number of ER’s/hospitals, number
of prescribers)
·Adjustment for year of cohort entry
·Percentage with hypoglycemia by year
·Baseline demographic characteristics of those with and without laboratory values (ie
HbA1c and creatinine) available in the 1 year previous

Appendices
Appendix A: Drug List

OHA drug list.xls

OHA drug list extra
BC.xls

Appendix B: Sample Tables

OHA and
hypoglycemia tables.xls

Appendix C: Cerner FSA Info

CERNER Pharmacy CERNER hospitals.xls
FSA.xls
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Appendix D: Baseline Characteristics

OHA and
OHA new
hypoglycemia baseline.txtbaselines.txt

Characteristic

Datasets Used

Other Details

Age

RPDB

Mean, median, SD
66-70
71-75
76-80
81-85
86-90
>90

Sex
Income quintile

RPDB
PSTLYEAR (using %getdemo)

Rural location
Year of cohort entry (index date)
LTC utilization
Charlson score

PSTLYEAR (using %getdemo)

Nephrologist visit in 1 year prior

OHIP

ODB

Measure of general
comorbidity based on
relative effects of a
combination of diseases or
risk factors on outcomes for
a given individual to show
expected mortality
reported as 0, 1, 2, or ≥ 3; if
there are no hospitalizations,
code as 0 and not as
‘missing’
First, identify physicians
who are Nephrologists: a
physician who, during the
study accrual period, had
both:
1) billed ≥ 25 OHIP fee
codes for “Nephrologist
consult” (can be same
patient, but have to be codes
billed on separate days; i.e.
no more than one OHIP
A135 code per day)

nephro codes.txt

AND
2) billed ≥ 50 OHIP
“dialysis” codes, with no
more than 1 code on a given
day (i.e. evidence of at least
50 separate days of codes.
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Note: some forms of acute
dialysis were excluded from
this dialysis list as this can
be billed by a physician
other than nephrologist i.e.
intensive care physicians or
during continuous venovenous hemodialysis)

ohip dialysis codes
for nephro consult .txt

Cardiologist visit

IPDB

Ophthalmologist visit

IPDB

Endocrinologist visit

IPDB

Internist visit

IPDB

Prescribing physician main specialty

IPDB

Alcoholism

Second, look for evidence of
any of the “Nephrologist
consult” OHIP Feecodes
billed by a nephrologist in
the past 1 year prior to
index date
Number of patients who
have seen a cardiologist at
least once in 1 year prior.
Defined by mainspecialty =
“CARDIOLOGY”
Number of patients who
have seen a cardiologist at
least once in 1 year prior.
Defined by mainspecialty =
“OPHTHALMOLOGY”
Number of patients who
have seen a cardiologist at
least once in 1 year prior.
Defined by mainspecialty =
“ENDOCRINOLOGY”
Number of patients who
have seen a cardiologist at
least once in 1 year prior.
Defined by mainspecialty =
“INTERNAL MEDICINE”
NEPHROLOGY
CARDIOLOGY
OPHTHALMOLOGY
ENDOCRINOLOGY
INTERNAL MEDICINE
GP/FP
Missing
Other

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Chronic kidney disease

CIHI-DAD
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Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Chronic liver disease

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Carotid ultrasound

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Coronary angiogram

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Coronary revascularization

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Echocardiography

CIHI-DAD
Source
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All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Holter monitoring

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Stress test

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Glycosylated hemoglobin

OHIP
Claim Type
ALL

Diabetic retinopathy

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Diabetes management

OHIP
Claim Type
NONLAB

Diabetes incentive

OHIP

Look in 1 year prior
(FYI – this is for GP)
Look in 1 year prior

Claim Type
NONLAB

Diabetes management by a specialist

OHIP
Claim Type
NONLAB

Diabetes management by a specialist
team

OHIP

Look in 1 year prior
(FYI – specialists can include
internists, endocrinologists, or
pediatricians)
Look in 1 year prior

Claim Type
(FYI – specialists in this case
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NONLAB

can mean internists or
endocrinologists)
Also show diabetes
management by a specialist OR
team in 1 year prior

PVD

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Heart failure

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

CABG

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Sepsis

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Pituitary issues

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
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diagnoses?
No

OHIP
Claim Type
NONLAB

Adrenal issues

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Thyroid issues

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

OHIP
Claim Type
NONLAB

Pancreatitis

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Cystic fibrosis

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Pancreatectomy

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Pancreatic Cancer

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
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‘AT’)
Include suspected/questionable
diagnoses?
No

Lab values if available

Fasting serum glucose
Serum glucose (random)
HbA1C

Gamma Dynacare
Glucose serum fasting – test
number 111G
Gamma Dynacare
Glucose serum random – test
number 111H
Gamma Dynacare
Hemoglobin A1C – test number
093D

Please provide mean, SD,
median, IQR
Please provide mean, SD,
median, IQR
Range of acceptable values for
HbA1C include 1 to 25%.
Values <1% and >25% will be
excluded. Values that do not lie
in the specified range are likely
errors.
Please provide mean, SD,
median, IQR

Serum creatinine

Gamma Dynacare
Type of test
Serum Creatinine
‘/home/sdixon/data/GD/fullSCr’
CERNER
Type of test
Serum creatinine in µmol/L
(Test_Done = “A”)
Hospital Stay
Inpatient (Disposition =
“Inpatient”)
Emergency Room (Disposition =
“Emergency Room”)
Outpatient (Disposition =
“Outpatient”)

GFR

Gamma Dynacare
Type of test
Serum Creatinine - variable:
“ckd_epi_egfr”
Serum creatinine
(main_gd_dec10tojan11_sent_mar11,
[main_gd_jan02tonov10_sent_dec10)
CERNER
Type of test
Serum creatinine in µmol/L
(Test_Done = “A”)
Hospital Stay
Inpatient (Disposition =
“Inpatient”)
Emergency Room (Disposition =
“Emergency Room”)
Outpatient (Disposition =
“Outpatient”)

Range of acceptable values for
serum creatinine include 102500 µmol/L. Values <10
µmol/L and >2500 µmol/L will
be excluded. Values that do not
lie in the specified range are
likely errors.
Please provide mean, SD,
median, IQR

For CERNER, use CKDEPI equation
=141 x min([serum creatinine in
umol/L /88.4 ]/κ, 1)α x
max([serum creatinine in
umol/L / 88.4]/κ, 1)-1.209 x
0.993Age x 1.018 [if Female] x
1.159 [if African American]

o

κ=0.7 for females and 0.9 for
males,
α= -0.329 for females and 0.411 for males,
min=the minimum of Scr/κ or 1,
max=the maximum of Scr/κ or
1.
Please provide mean, SD,
median, IQR
Also put into the following
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categories:
eGFR >60
45-59
30-44
15-29
<15 mL/min/1.73m2

Medication
Acetohexamide
ACE inhibitors
ARBs
Aliskiren
Beta blockers
Ezetimibe
Fibrates
Glucose test strips
Loop diuretics
Potassium sparing diuretics
Statins
Thiazide diuretics
Gatifloxacin/Levofloxacin
Pentamidine
Quinine
Indomethacin
Tacrolimus/sirolimus
Clonidine
Chloramphenicol
H2 receptor antagonists
Clarithromycin
Cyclosporine
Fluconazole/voriconazole/miconazole
Pegvisomant
Probenecid
Rifampin
Amiodarone
Valproic acid
Aprepitant
Bosentan
Carbamazepine
Antidepressants
Protease inhibitors
Atypical antipsychotics
Corticosteroids
Sulfonamides
MAOI Inhibitors
Barbiturates
Tetracycline
Danazol
Thyroid hormone
Androgens
Disopyramine
Guanethidine
Ifosfamide

DCLASS
BC_ACT
BC_ACE
BC_ARB
BC_ALI
BC_BBL
BC_EZE
BC_FIB
BC_STR
BC_LOP
BC_KSD
BC_STA
BC_TZD
BC_GAT
BC_PEN
BC_QUI
BC_IND
BC_LIM
BC_CLO
BC_CHL
BC_HRA
BC_CLA
BC_CYC
BC_FLV
BC_PEG
BC_PBD
BC_RIF
BC_AMI
BC_VAL
BC_APR
BC_BOS
BC_CAR
BC_DEP
BC_PRO
BC_APS
BC_CCS
BC_SUL
BC_MAO
BC_BAR
BC_TET
BC_DAN
BC_THY
BC_TES
BC_DIS
BC_GUA
BC_IFO
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Phenylbutazone
Diazoxide
Isoniazid
Colesevelam
Reserpine

BC_PHE
BC_DIA
BC_ISO
BC_COL
BC_RES
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Table 1. Checklist of recommendations for reporting of observational studies using
the STROBE guidelines

Title and abstract

Item
No

Recommendation

1

(a) Indicate the study’s design with a commonly
used term in the title or the abstract
(b) Provide in the abstract an informative and
balanced summary of what was done and what was
found

Reported
Abstract
Abstract

Introduction
Background/rationale

2

Objectives

3

Explain the scientific background and rationale for
the investigation being reported
State specific objectives, including any prespecified hypotheses

Introduction
Introduction

Methods
Study design

4

Setting

5

Participants

6

Variables

7

Data sources/
measurement

8

Bias

9

Study size

10

Quantitative
variables

11

Statistical methods

12

Present key elements of study design early in the
paper
Describe the setting, locations, and relevant dates,
including periods of recruitment, exposure, followup, and data collection
(a) Give the eligibility criteria, and the sources and
methods of selection of participants. Describe
methods of follow-up
(b) For matched studies, give matching criteria and
number of exposed and unexposed
Clearly define all outcomes, exposures, predictors,
potential confounders, and effect modifiers. Give
diagnostic criteria, if applicable
For each variable of interest, give sources of data
and details of methods of assessment
(measurement). Describe comparability of
assessment methods if there is more than one group
Describe any efforts to address potential sources of
bias
Explain how the study size was arrived at
Explain how quantitative variables were handled in
the analyses. If applicable, describe which
groupings were chosen and why
(a) Describe all statistical methods, including those
used to control for confounding
(b) Describe any methods used to examine

Methods
Methods

Methods
Not applicable
Methods and
Appendix D
Table 2 and 3
Methods and
Appendix D
Table 2 and 3
Methods
Not applicable
Methods
Methods
Methods
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subgroups and interactions
(c) Explain how missing data were addressed
(d) If applicable, explain how loss to follow-up was
addressed
(e) Describe any sensitivity analyses

Not applicable
Not applicable
Not applicable

Results

Participants

Descriptive data

Outcome data

Main results

Other analyses

13
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15

16

17

(a) Report numbers of individuals at each stage of
study—e.g. numbers potentially eligible, examined
for eligibility, confirmed eligible, included in the
study, completing follow-up, and analyzed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
(a) Give characteristics of study participants (e.g.
demographic, clinical, social) and information on
exposures and potential confounders
(b) Indicate number of participants with missing
data for each variable of interest
(c) Summarize follow-up time (e.g. average and
total amount)
Report numbers of outcome events or summary
measures over time
(a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision
(e.g. 95% confidence interval). Make clear which
confounders were adjusted for and why they were
included
(b) Report category boundaries when continuous
variables were categorized
(c) If relevant, consider translating estimates of
relative risk into absolute risk for a meaningful time
period
Report other analyses done—e.g. analyses of
subgroups and interactions, and sensitivity analyses

Results
Results
Results, Table
7, and Appendix
D Table 4
Not applicable
Not applicable
Results

Results

Results
Not applicable
Not applicable

Discussion
Key results

18

Limitations

19

Interpretation

20

Generalizability

21

Summarize key results with reference to study
objectives
Discuss limitations of the study, taking into account
sources of potential bias or imprecision. Discuss
both direction and magnitude of any potential bias
Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other
relevant evidence
Discuss the generalizability (external validity) of
the study results

Discussion
Discussion

Discussion

Discussion
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Other information
Funding

22

Give the source of funding and the role of the
funders for the present study and, if applicable, for
the original study on which the present article is
based

Financial
Disclosures
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Table 2. Coding definitions for demographic and comorbid conditions
Characteristics/
Condition
Age

RPDB

Sex

RPDB

Income quintile

Statistics
Canada
Statistics
Canada
CIHIDAD
OHIP

Rural location
Chronic kidney
disease

Database

Codes

ICD 9: "4030", "4031", "4039", "4040", "4041", "4049",
"585", "586", "5888", "5889", "2504"
ICD 10: "E102", "E112", "E132", "E142", "I12", "I13",
"N08", "N18", "N19"

Chronic liver
disease

CIHIDAD
OHIP

OHIP DX: "403", "585"
ICD 9: "4561", "4562", "070", "5722", "5723", "5724",
"5728", "573", "7824", "V026", "2750", "2751", "7891",
"7895", "571"
ICD 10: "B16", "B17", "B18", "B19", "I85", "R17",
"R18", "R160", "R162", "B942", "Z225", "E831",
"E830", "K70", "K713", "K714", "K715", "K717",
"K721", "K729", "K73", "K74", "K753", "K754",
"K758", "K759", "K76", "K77"
OHIP DX: "571", "573", "070"

Any cancer

CIHI
OHIP

OHIP FEE: "Z551", "Z554"
ICD 9: "V10", "140", "141", "142", "143", "144", "145",
"146", "147", "148", "149", "150", "151", "152", "153",
"154", "155", "156", "157", "158", "159", "160", "161",
"162", "163", "164", "165", "170", "171", "172", "173",
"174", "175", "176", "179", "180", "181", "182", "183",
"184", "185", "186", "187", "188", "189", "190", "191",
"192", "193", "194", "1950", "1951", "1952", "1953",
"1954", "1955", "1958", "196", "197", "198", "1990",
"1991", "2000", "2001", "2002", "2008", "2010", "2011",
"2012", "2014", "2015", "2016", "2017", "2019", "2020",
"2026", "2028", "2029", "203", "204", "205", "206",
"207", "208", "230", "231", "232", "233", "234"
ICD 10: "80003", "80006", "80013", "80023", "80033",
"80043", "80102", "80103", "80106", "80113", "80123",
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"80203", "80213", "83123", "87202", "87203", "959",
"965", "966", "967", "968", "969", "970", "971", "980",
"982", "984", "985", "986", "987", "988", "989", "990",
"991", "993", "C00", "C01", "C02", "C03", "C04",
"C05", "C06", "C07", "C08", "C09", "C10", "C11",
"C12", "C13", "C14", "C15", "C16", "C17 C18", "C19",
"C20", "C21", "C22", "C23", "C24", "C25", "C26",
"C30", "C31", "C32", "C33", "C34", "C37", "C38",
"C39", "C40", "C41", "C43", "C44", "C45”, “C46",
"C47", "C48", "C49", "C50", "C51", "C52", "C53",
"C54", "C55", "C56", "C57", "C58", "C60", "C61",
"C62", "C63", "C64", "C65", "C66", "C67", "C68",
"C69", "C70", "C71", "C72", "C73", "C74", "C75"
,"C76", "C77", "C78", "C79", "C80", "C81", "C82",
"C83", "C84", "C85", "C90", "C91", "C92", "C93",
"C94", "C95", "C96", "C97", "D00", "D01", "D02",
"D03", "D04", "D05", "D06", "D07", "D09"

Coronary artery
disease
(excluding
angina)

CIHIDAD
OHIP

OHIP DX: "140", "141", "142", "143", "144", "145",
"146", "147", "148", "149", "150", "151", "152", "153",
"154", "155", "156", "157", "158", "159", "160", "161",
"162", "163 164"," 165", "170", "171", "172", "173",
"174", "175", "179", "180", "181", "182", "183", "184",
"185", "186", "187", "188", "189 190", "191", "192",
"193", "194", "195", "196", "197", "198", "199", "200",
"201", "202", "203", "204", "205", "206", "207", "208"
ICD 9: "412", "410"
ICD 10: "I21", "I22", "Z955", "T822"
CCI: "1IJ50", "1IJ76"
CCP: "4801", "4802", "4803", "4804", "4805", "481",
"482", "483"
OHIP FEE: "R741", "R742", "R743", "G298", "E646",
"E651", "E652", "E654", "E655", "Z434", "Z448"

Congestive heart
failure

CIHIDAD
OHIP

OHIP DX: "410", "412"
ICD 9: "425", "5184", "514", "428"
ICD 10: "I500", "I501", "I509", "I255", "J81"
CCP: "4961", "4962", "4963", "4964"
CCI: "1HP53", "1HP55", "1HZ53GRFR",
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"1HZ53LAFR", "1HZ53SYFR"
OHIP FEE: "R701", "R702", "Z429"

Peripheral
vascular disease

CIHIDAD
OHIP

OHIP DX: "428"
ICD 9: "4402", "4408", "4409", "5571", "4439", "444"
ICD 10: "I700", "I702", "I708", "I709", "I731", "I738",
"I739", "K551"
CCP: "5125", "5129", "5014", "5016", "5018", "5028",
"5038"
CCI: "1KA76", "1KA50", "1KE76", "1KG26",
"1KG50", "1KG57", "1KG76MI", "1KG87"

Dementia

CIHIDAD
OHIP

OHIP FEE: "R787", "R780", "R797", "R804", "R809",
"R875", "R815", "R936", "R783", "R784","R785",
"E626", "R814", "R786", "R937", "R860", "R861",
"R855", "R856", "R933", "R934", "R791", "E672",
"R794", "R813", "R867", "E649"
ICD 9: "2900", "2901", "2903", "2904", "2908", "2909",
"2948", "2949", "3310", "3311", "3312", "2941", "797"
ICD 10: "F065", "F066", "F068", "F069", "F09", "F00",
"F01", "F02", "F03", "F051", "G30", "G31", "R54"

Stroke/
Transient
ischemic attack

CIHIDAD

Neuropathy

CIHIDAD

OHIP DX: "290","331", "797"
ICD 9: "430", "431", "434", "435", "436"
ICD 10: "I630", "I631", "I632", "I633", "I634", "I635",
"I638", "I639", "I64", "H341", "I600", "I601", "I602",
"I603", "I604", "I605", "I606", "I607", "I609", "I61",
"G450", "G451", "G452", "G453", "G458", "G459"
ICD 9: "3572"
ICD 10: “E1040”,”E10400”,
“E10401”,”E10402”,“E10403”, “E10404”, “E10409”,
“E1041”,
“E10410”, “E10411”, “E10412”,
“E10413”, “E10414”, “E10419”, “E1042”, “E10420”,
“E10421”, “E10422”,
“E10423”,“E10424”,“E10429”,“E10480”,“E10481”,“E1
0482”, “E10483”,“E10484”, “E10489”, “E10490”,
“E10491”, “E10492”, “E10493”, “E10494”, “E10499”,
“E1140”, “E11400”, “E11401”, “E11402”, “E11403”,
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Retinopathy

Number of
cholesterol tests
Number of
HbA1c tests
Number of
creatinine tests
Number of
glucose tests
Major eye
examination

CIHIDAD

“E11404”, “E11409”, “E1141”, “E11410”, “E11411”,
“E11412”, “E11413”, “E11414”, “E11419”, “E1142”,
“E11420”, “E11421”, “E11422”, “E11423”, “E11424”,
“E11429”, “E11480”, “E1148”, “E11482”, “E11483”,
“E11484”, “E11489”, “E11490”, “E11491”, “E11492”,
“E11493”, “E11494”, “E11499”, “E1340”, “E13400”,
“E13401”, “E13402”, “E13403”, “E13404”, “E13409”,
“E1341”, “E13410”, “E13411”, “E13412”, “E13413”,
“E13414”, “E13419”, “E1342”, “E13420”, “E13421”,
“E13422”, “E13423”, “E13424”, “E13429”, “E13480”,
“E13481”, “E13482”, “E13483”, “E13484”, “E13489”,
“E13490”, “E13491”, “E13492”, “E13493”, “E13494”, “
“E13499”, “E1440”, “E14400”, “E14401”, “E14402”,
“E14403”, “E14404”, “E14409”, “E1441”, “E14410”,
“E14411”, “E14412”, “E14413”, “E14414”, “E14419”,
“E1442”, “E14420”, “E14421”, “E14422”, “E14423”,
“E14424”, “E14429”, “E14480”, “E14481”, “E14482”,
“E14483”, “E14484”, “E14489”, “E14490”, “E14491”,
“E14492”, “E14493”, “E14494”, “E14499”, “G590”,
“G632”
ICD 9: “36201”, “36202”, “36210”, “36212”, “36229”

OHIP

ICD 10: “E1030”, “E10300”, “E10301”, “E10302”,
“E10303”, “E10304”, “E10309”, “E1031”, “E10310”,
“E10311”, “E10312”, “E10313”, “E10314”, “E10319”,
“E1032”, “E10320”, “E10321”, “E10322”, “E10323”,
“E10324”, “E10329”, “E1033”, “E10330”, “E10331”,
“E10332”, “E10333”, “E10334”, “E10339”, “E10340”,
“E10341”, “E10342”, “E10343”, “E10344”, “E10349”,
“E1130”, “E11300”, “E11301”, “E11302”, “E11303”,
“E11304”, “E11309”, “E1131”, “E11310”, “E11311”,
“E11312”, “E11313”, “E11314”, “E11319”, “E1132”,
“E11320”, “E11321”, “E11322”, “E11323”, “E11324”,
“E11329”, “E1133”, “E11330”, “E11331”, “E11332”,
“E11333”, “E11334”, “E11339”, “E11340”, “E11341”,
“E11342”, “E11343”, “E11344”, “E11349”, “H360”
OHIP FEE: “L055”

OHIP

OHIP FEE: “L093"

OHIP

OHIP FEE: OHIP FEE: "L065", "L067", "L068"

OHIP

OHIP FEE: "L111"

OHIP

OHIP FEE: "A112", "A233", "A234", "A235", "A236",
A239", "V401", "V406", "V402"
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Abbreviations: CIHI, Canadian Institute for Health Information’s Discharge Abstract
Database; CCI, Canadian Classification of Health Interventions; CCP, Canadian
Classification of Diagnostic, Therapeutic, and Surgical Procedures; HbA1c, hemoglobin
A1c; ICD 9, International Classification of Diseases 9th Revision; ICD 10, International
Classification of Diseases 10th Revision; OHIP, Ontario Health Insurance Plan; RPDB,
Registered Persons Database of Ontario
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Table 3. Coding definitions for hospital presentation with hypoglycemia

Condition

Database

Codes

Hypoglycemia

CIHI-DAD
NACRS

ICD 10: E15, E160, E161,
E162, E1063, E1163,
E1363, E1463

Abbreviations: CIHI, Canadian Institute for Health Information Discharge Abstract
Database; ICD 10, International Classification of Diseases 10th Revision; NACRS,
National Ambulatory Care Reporting System Database
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Table 4. Baseline characteristics of patients with newly treated diabetes
April 1, 2002
N=3,498
%

April 1, 2007
N=5,863
%

April 1, 2012
N=4,478
%

Age (yr)
Mean (SD)
Median (IQR)
66-69
70-74
75-79
80-84
85-89
90+
Sex - Female
Income
quintile
Missing
1 (lowest)
2
3
4
5 (highest)
Rural
Missing
No
Yes
Comorbiditiesa
Chronic
kidney disease
Chronic liver
disease
Any cancer
Coronary
artery disease
(excluding
cancer)
Congestive
heart failure
Peripheral
vascular
disease

73 (69-78)
926
1083
801
416
200
72
1686

26.47%
30.96%
22.90%
11.89%
5.72%
2.06%
48.20%

74.45
(6.43)
73 (6978)
1599
1661
1337
780
355
131
2765

9
797
834
679
625
554

0.26%
22.78%
23.84%
19.41%
17.87%
15.84%

≤5
2955
542

74.22 (6.24)

74.31 (6.63)

27.27%
28.33%
22.80%
13.30%
6.05%
2.23%
47.16%

73 (69-79)
1314
1275
911
570
297
111
2125

29.34%
28.47%
20.34%
12.73%
6.63%
2.48%
47.45%

24
1238
1261
1110
1118
1112

0.41%
21.12%
21.51%
18.93%
19.07%
18.97%

8
882
947
923
901
817

0.18%
19.70%
21.15%
20.61%
20.12%
18.24%

--84.48%
15.49%

≤5
5146
715

--87.77%
12.20%

≤5
3890
587

--86.87%
13.11%

167

4.77%

575

9.81%

396

8.84%

130
920

3.72%
26.30%

236
1508

4.03%
25.72%

170
1153

3.80%
25.75%

1136

32.48%

1,832

31.25%

1202

26.84%

559

15.98%

800

13.64%

513

11.46%

100

2.86%

129

2.20%

55

1.23%
126
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Dementia
Stroke/TIA
Neuropathy
Retinopathy
Investigationsb
Mean (SD)
number
cholesterol
tests
Median (IQR)
cholesterol
tests
Mean (SD)
HbA1c tests
Median (IQR)
HbA1c tests
Mean (SD)
creatinine tests
Median (IQR)
creatinine tests
Mean (SD)
glucose tests
Median (IQR)
glucose tests
At least 1 eye
exam
Laboratory
Datac
At least 1
HbA1c
outpatient lab
value
Mean (SD)
HbA1c (%)
Mean (SD)
HbA1c
(mmol/mol)
Median (IQR)
HbA1c
Median (IQR)
HbA1c
(mmol/mol)

271
139
≤5
13

7.75%
3.97%
--0.37%

488
185
21
44

8.32%
3.16%
0.36%
0.75%

444
135
29
17

9.92%
3.01%
0.65%
0.38%

0.96 (1.15)

---

1.19
(1.19)

---

1.11 (1.07)

---

1 (0-1)

---

---

1 (0-2)

---

1.25 (1.50)

---

1 (0-2)
1.49
(1.62)

---

1.45 (1.35)

---

1 (0-2)

---

---

1 (0-2)

---

1.48 (1.91)

---

1 (0-2)
1.84
(2.14)

---

1.76 (1.91)

---

1 (0-2)

---

---

1 (1-2)

---

2.03 (2.44)

---

1 (1-2)
1.92
(2.04)

---

1.62 (1.59)

---

1 (0-3)

---

2 (1-3)

---

1 (0-2)

---

1,113

31.82%

1,887

32.18%

1,127

25.17%

---

---

21.06%

994

22.20%

---

---

1,235
6.8%
(1.1%)

---

7.2% (1.2%)

---

---

51 (12)
6.6%
(6.1%7.2%)

---

49 (4355)

55 (13.1)

---

6.9% (6.5%7.5%)

---

52 (48-58)

127

128

Abbreviations: TIA transient ischemic attack, SD standard deviation, IQR interquartile
range, HbA1c glycosylated hemoglobin
For reasons of privacy, cell sizes less than 6 are not presented.
a
Comorbidities were examined in the 5 years prior.
b
Investigations were examined in the 1 year prior.
c
Lab values were available in the 1 year prior.
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Table 5. Timeline of safety events during the study period– thiazolidinediones
October
2006
January
2007
February
2007
May 2007

Pioglitazone added to the province’s general benefit drug formulary

June 2007

Meta-analysis on cardiac safety of rosiglitazone published in the New
England Journal of Medicine 4
Black box warning issued for rosiglitazone in the United States 5

Nov 2007

Rosiglitazone added to the province’s general benefit drug formulary
Safety signals emerge re: fracture risk with rosiglitazone 1
Regulatory warnings re: cardiac safety of rosiglitazone 2,3

June 2009

Funding status for thiazolidinediones changed from General Benefit to the
Exceptional Access Program in Ontario 6

Sept 2010

Prescribing restrictions on thiazolidinediones placed in the United States 7

June 2011

Regulatory attention to risk of bladder cancer with pioglitazone therapy 8

1. Health Canada. Important safety information on rosiglitazone-containing products:
AVANDIA®, AVANDAMET® and AVANDARYL™ [Internet]. 2007.
http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2007/13994a-eng.php,
Accessed Jan 30, 2015.
2. Health Canada. Cardiac Safety of Avandia (rosiglitazone maleate) - For Health
Professionals [Internet]. 2007. http://www.healthycanadians.gc.ca/recall-alert-rappelavis/hc-sc/2007/14440a-eng.php, Accessed Jan 30, 2015
3.US Food and Drug Administration. Information for Healthcare Professionals
Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) [Internet].
http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor
PatientsandProviders/ucm143460.htm, Accessed Jan 30, 2015
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and
death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
5.US Food and Drug Administration. FDA Adds Boxed Warning for Heart-related Risks
to Anti-diabetes Drug Avandia [Internet]. 2007. http://www.fda.gov/NewsEvents/
Newsroom/ PressAnnouncements/2007/ucm109026.htm, Accessed Jan 30, 2015.
6.Ontario Ministry of Health and Long-term Care. Change in Funding Status
Rosiglitazone and Pioglitazone [Internet]. 2009. http://www.health.gov.on.ca/en/pro/
programs/drugs/opdp_eo/notices/notices_docs/tzd_faq.pdf, Accessed Jan 30, 2015.
7.US Food and drug Administration. FDA significantly restricts access to the diabetes
drug Avandia [Internet]. 2010. http://www.fda.gov/ Drugs/DrugSafety/Postmarket
DrugSafetyInformationforPatientsandProviders/ucm226956.htm, Accessed Jan 30, 2015.
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8. Health Canada. Health Canada reviewing diabetes drug pioglitazone (Actos) and
potential risk of bladder cancer [Internet]. http://www.healthycanadians.gc.ca/recallalert-rappel-avis/hc-sc/2011/13617a-eng.php, Accessed 30 Jan 2015.
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Figure 1. Mono and combination therapy 2002-2013
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Figure 2. Insulin mono and combination therapy 2002-2013
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Percentage of insulin combination users

Figure 3. Oral antihyperglycemic medication prescriptions in insulin combination
therapy users 2002-2013
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*Drugs prescribed to less than 5% not illustrated (acarbose, acetohexamide,
chlorpropamide, glimepiride, nateglinide, repaglinide, tolbutamide)
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Percentage of patients with newly treated diabetes

Figure 4. Antihyperglycemic medication prescriptions in patients with newly treated
diabetes 2002-2013
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Figure 5. Mono and combination therapy in patients with newly treated diabetes
2002-2013
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Figure 6. Insulin mono/combination therapy in patients with newly treated diabetes
2002-2013
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Appendix E
Dataset Creation Plan for “Trends in Antihyperglycemic
Medication Prescriptions and Hypoglycemia in Older Adults:
2002-2013”
TRIM Number of Study
Research Program

KDT

Study Team (including
contact information)

Kristin Clemens
Amit Garg
Salimah Shariff
Kuan Liu
Eric McArthur

Who will be responsible
for DCP updates?

KC

PIA Approved?

Yes

DCP update history

Version 1 KC (July 21, 2014)
Version 2 KC (July 29th, 2014 after meeting with S.S.)
Version 3 KC (September 14th, 2014 after meeting with IH, SS and KL)
Version 4 KC (October 16 2014 after feedback from faculty scholars session and
meeting with AG, SS, KL)

Trends DCP
Updates.docx

Hypoglycemia is one of the most common acute complications of diabetes management.
If severe it may result in hospital presentation, cardiovascular compromise, neurological
dysfunction and even death.

Short Description of
Research Question

In the current project we will aim to examine trends in hypoglycemic agent drug use,
demographics, comorbidities and hospital encounters for hypoglycemia in a cohort of
adult diabetic patients from 2002 until 2013. To our knowledge such a detailed
examination has not been carried out in our region previously.
We anticipate that this project will help to provide insight into the changing diabetes
population and their disease complications and help to improve the care of patients with
this disease.

Study Design

Time series analysis
RPDB (April 2002 to March 2013)

List of Datasets Used

ODB (April 2001 to March 2013)
Population
Age 65+
137

138

Is druglist with DIN & DCLASS provided in Appendix?
Yes

CIHI-DAD (April 1997 to March 2013)
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
OHIP (April 1997 to March 2013)
Claim Type
Nonlab
Lab
Codes
Fee codes
Diagnostic codes
NACRS (April 1997 to March 2013)
Source
Emergency Department visits
Include planned visits

No
Include suspected/questionable diagnoses?
No
Gamma-Dynacare (April 2001-March 2013)
Dataset
Southwestern Ontario
All of Ontario
Type of test
Serum creatinine ‘/home/sdixon/data/GD/fullSCr’
Hemoglobin A1C – test number 093D
CERNER (April 2001-March 2012)
File name: /ices/CDP/cerner/cerner_apr99_dec10.sas7bdat
Type of test
Serum creatinine (Test_Done=”A”)
Hemoglobin A1C (Test Done=”B”)
Hospital Stay
Inpatient
Emergency Room
Outpatient
ODD (April 2002-March 2013)

138

139

Defining the Cohort
Cohort Inclusion/ For each 3 month interval, identify patients with diabetes as defined by the Ontario Diabetes
Denominator (for Database)
each study
interval)
See Appendix C and D for variable definitions
1.
2.
3.
4.
5.

Exclusions (to be
applied during
each study
interval)

6.

Missing or invalid IKN
Missing age or sex
Invalid ages (negative ages or age >105)
Death on or before the beginning of the study interval
Non Ontario residents (individuals without the RPDB variable “prdcddablk” beginning
with “35”)
Age ˂66 years at the beginning of the study interval

Time Frame Definitions

Observation Window

Accrual Start/End Dates

April 1, 2002-March 31, 2013

Study intervals

The 11 year (fiscal year) study will be divided into 44 intervals (each interval will be
3 months in duration)
Thus, each fiscal year will be divided into 4 quarters, defined by calendar months
Quarter 1: April, May, June
Quarter 2: July, August, September
Quarter 3: October November December
Quarter 4: January February March

Look back Window(s)

1 year for baseline medications
5 years for comorbidities
1 year for laboratory data
1 year for investigations

Variable Definitions
Main Exposure/
Numerator

Users of at least one of the following study hypoglycemic agents during the study interval
-Insulin
-Acetohexamide
-Chlorpropamide
-Tolbutamide

139
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-Glyburide
-Gliclazide
-Glimepiride
-Repaglinide
-Nateglinide
-Pioglitazone
-Rosiglitazone
-Metformin
-Acarbose
-Sitagliptin
-Saxagliptin
-Sitagliptin-Metformin
*See Appendix B and C for drug list and DCLASS definitions
We will determine the baseline characteristics of to examine if they remain similar over time.
Baseline
Characteristics
1. Age
(determine at the
2. Sex
beginning of 3
3. Income quintile
study quarters –
4. Rural location
April 1, 2002,
April 1, 2007,
April 1, 2012)
In the previous 5 years, evidence of the following:
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

Chronic kidney disease
Chronic liver disease
Cancer
Retinopathy
Neuropathy
Dementia
Stroke/TIA
Cardiovascular disease (excluding angina)
Congestive heart failure
Peripheral vascular disease

For those with evidence of an HbA1c test in the 1 year previous (Gamma Dynacare
OR CERNER):
1. Mean, SD, Median, IQR HbA1c
*Note if multiple HbA1c tests for an individual, use the most recent value
In the previous 1 year:
1. Mean, SD, median, IQR number of HbA1c tests
2. Mean, SD, median, IQR number cholesterol tests
3. Mean, SD, median, IQR number of creatinine tests
4. N (%) with at least one major eye exam/ophthalmology assessment
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*See Appendix A for sample tables, B for drug lists and C and D for variable definitions
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Outline of Analysis Plan
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1.

Cohort creation
- Apply inclusion and exclusion criteria during each interval to determine denominator for each interval
(Sample Table 1)
2. Prescriptions
-Determine drug use for each interval (ie numerator). Examine this by individual DCLASS
(Sample Table 2), number of hypoglycemic agent drugs prescribed (Sample Table 3), number of
NEW drug users (Sample Table 4) where NEW hypoglycemic agent users are those with no
evidence of ANY study hypoglycemic agent prescription in the previous 1 year
-For NEW hypoglycemic agent users, examine also the number of hypoglycemic agent drugs prescribed
during the interval (Sample Table 13)
-Notes: For those prescribed sitagliptin-metformin combination, count a script for each DCLASS
separately (ie. patient prescribed sitagliptin-metformin will have evidence of a prescription for both
sitagliptin and for metformin)
For calculation of general drug prescription rate, make denominator those prescribed hypoglycemic agents
rather than the entire diabetic population (see Table 2 amendments)
-For insulin users, examine number of other hypoglycemic agents prescribed (Table 11)
-For those on insulin combination therapy (ie evidence of insulin and at least 1 other hypoglycemic agent
during the interval) show rates of other DCLASS prescriptions (Table 12)
2.

Baseline characteristics Show number and proportion with the characteristics listed in Appendix C at the
beginning of 3 study intervals (April 1, 2002, April 1, 2007, April 1, 2012) for all diabetics (Table 6), for
those prescribed at least one hypoglycemic agent (Table 9), and for NEW hypoglycemic agent users (Table
10)

3.

Hypoglycemia
Examine hospital encounters for hypoglycemia for each study interval. Show the total number of
hypoglycemic events during each interval (Sample Table 7)
For the calculation of hypoglycemia rate, change denominator to those prescribed any hypoglycemic drug
during the interval rather than the entire diabetic population
*Note: Definitions of hypoglycemic events outlined in Appendix D
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Appendix
Appendix A – Sample Tables

Trends Tables.xlsx
Appendix B – Drug Lists

Trends Druglist.xlsx

Appendix C – Variable Definitions

TrendsBaselines.txt

Appendix D – Variable Tables
Table 1. Denominator Definition
Characteristic
Diabetes with at least one
hypoglycemic agent prescription
(ie. diabetes drug users)

Dataset Used
ODD
ODB

Other details

Table 2: Study Medications
Medication Name
Insulin

DCLASS
S_INS

Glyburide

S_GLY

Gliclazide

S_GLI

Repaglinide

S_REP

Metformin

S_MET

Pioglitazone

S_PIO

Rosiglitazone

S_ROS

Acarbose

S_ACA

Sitagliptin -Metformin

S_SIM

Sitagliptin

S_SIT

Saxagliptin

S_SAX

Tolbutamide

S_TOL

Acetohexamide

S_ACT

Chlorpropamide

S_CHL

Glimepiride

S_GLM
144

145

Nateglinide

S_NAT

Table 3. Baseline Characteristics
Characteristic
Year of index date

Dataset Used

Other details

Age

RPDB

Mean, SD, Median, IQR, 66-69,
70-74, 75-79, 80-84, 85-89, ≥90

Sex

RPDB

Income quartile

PSTLYEAR
%getdemo

1, 2, 3, 4, 5, missing

Residential status

PSTLYEAR
%get demo

Rural, urban, missing

CKD

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

For main cohort only
Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
Retinopathy

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No
NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
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Dementia

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
Liver Disease

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
Coronary artery disease (excluding
angina)

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
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OHIP
Claim Type
NONLAB
Stroke/TIA

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
Peripheral Vascular Disease

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
Cancer

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
147
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Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
Neuropathy

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
CHF

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or
‘AT’)
Include suspected/questionable
diagnoses?
No

Report as N (%)

NACRS
Source
Emergency Department visits
Include planned visits
No
OHIP
Claim Type
NONLAB
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HbA1c value

Gamma-Dynacare
Dataset
Southwestern Ontario
All of Ontario

Report as mean, SD, median, IQR

Type of test
Hemoglobin A1C – test number
093D
CERNER
File name:
/ices/CDP/cerner/cerner_apr99_dec
10.sas7bdat
Type of test
Hemoglobin A1C (Test
Done=”A”)
Hospital Stay
Inpatient
Emergency Room
Outpatient
HbA1c test

OHIP

Report as mean, SD, median, IQR

Claim Type
All
Code Types
Feecodes
Cholesterol test

OHIP

Report as mean, SD, median, IQR

Claim Type
All
Code Types
Feecodes
Creatinine test

OHIP

Report as mean, SD, median, IQR

Claim Type
All
Code Types
Feecodes
Glucose test

OHIP

Report as mean, SD, median, IQR

Claim Type
All
Code Types
Feecodes
Major eye exam/optho assessment

OHIP

Report as N(%)

Claim Type
All
Code Types
Feecodes
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